BRIGHTFOCUS FOUNDATION: Form 990, tax year 2023
View the entire original 990 at ProPublica ↗
- Organization
- BRIGHTFOCUS FOUNDATION (EIN 23-7337229)
- Tax period
- 2023-04-01 to 2024-03-31
- Filed
- 2024-12-05
- IRS object ID
- 202413409349300636
- Schema version
- 2023v5.1
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule M
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2024-12-05T13:40:00-06:00 | ReturnTs |
| Tax Period End | 2024-03-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 881478669 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | CBIZ ADVISORS LLC | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1899 L STREET NW 850 | AddressLine1Txt |
| City | WASHINGTON | CityNm |
| State Abbreviation | DC | StateAbbreviationCd |
| ZIP | 20036 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2023-04-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 237337229 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | BRIGHTFOCUS FOUNDATION | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | BRIG | BusinessNameControlTxt |
| Phone | 3019483244 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 22512 GATEWAY CENTER DRIVE | AddressLine1Txt |
| City | CLARKSBURG | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 20871 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | STACY PAGOS HALLER | PersonNm |
| Person Title | PRESIDENT/CEO | PersonTitleTxt |
| Phone | 3019483244 | PhoneNum |
| Signature | 2024-12-04 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IRS Responsible Prty Info Curr | Yes (1) | IRSResponsiblePrtyInfoCurrInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | FRANK SMITH | PreparerPersonNm |
| PTIN | P00639053 | PTIN |
| Phone | 2022274000 | PhoneNum |
| Preparation | 2024-12-04 | PreparationDt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2023 | TaxYr |
| Build TS | 2024-10-15 13:58:12Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | STACY PAGOS HALLER | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 22512 GATEWAY CENTER DRIVE | AddressLine1Txt |
| City | CLARKSBURG | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 20871 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $99,554,872 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.BRIGHTFOCUS.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1973 | FormationYr |
| Legal Domicile State | DC | LegalDomicileStateCd |
| Activity Or Mission | BRIGHTFOCUS FOUNDATION (BRIGHTFOCUS) SEEKS A WORLD FREE FROM DISEASES OF MIND AND SIGHT. | ActivityOrMissionDesc |
| Voting Members Governing Body | 11 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 11 | VotingMembersIndependentCnt |
| Total Employee | 69 | TotalEmployeeCnt |
| Total Volunteers | 70 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $43,451,535 | PYContributionsGrantsAmt |
| CY Contributions Grants | $43,373,203 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $0 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $0 | CYProgramServiceRevenueAmt |
| PY Investment Income | -$268,284 | PYInvestmentIncomeAmt |
| CY Investment Income | $4,702,264 | CYInvestmentIncomeAmt |
| PY Other Revenue | $710,546 | PYOtherRevenueAmt |
| CY Other Revenue | $587,403 | CYOtherRevenueAmt |
| PY Total Revenue | $43,893,797 | PYTotalRevenueAmt |
| CY Total Revenue | $48,662,870 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $14,321,603 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $10,704,093 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $6,392,782 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $6,876,671 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $942,971 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $952,781 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $12,200,813 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $26,850,858 | PYOtherExpensesAmt |
| CY Other Expenses | $27,683,861 | CYOtherExpensesAmt |
| PY Total Expenses | $48,508,214 | PYTotalExpensesAmt |
| CY Total Expenses | $46,217,406 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | -$4,614,417 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $2,445,464 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $58,626,477 | TotalAssetsBOYAmt |
| Total Assets EOY | $63,464,652 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $35,064,709 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $37,245,915 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $23,561,768 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $26,218,737 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | BRIGHTFOCUS FOUNDATION FUNDS EXCEPTIONAL RESEARCH WORLDWIDE TO DEFEAT ALZHEIMER'S DISEASE, MACULAR DEGENERATION, AND GLAUCOMA AND PROVIDES EXPERT INFORMATION ON THESE HEARTBREAKING DISEASES. PLEASE REFER TO SCHEDULE O FOR A COMPLETE OVERVIEW OF OUR MISSION. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $17,770,389 | ExpenseAmt |
| Grant | $6,604,227 | GrantAmt |
| Desc | ALZHEIMER'S DISEASE RESEARCH (ADR)PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR ALZHEIMER'S DISEASE RESEARCH. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $8,973,678 | ExpenseAmt |
| Grant | $3,334,998 | GrantAmt |
| Desc | MACULAR DEGENERATION RESEARCH (MDR)PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR MACULAR DEGENERATION RESEARCH. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $2,058,076 | ExpenseAmt |
| Grant | $764,868 | GrantAmt |
| Desc | NATIONAL GLAUCOMA RESEARCH (NGR) PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR NATIONAL GLAUCOMA RESEARCH. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Expenses | $28,802,143 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | Yes (1) | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | Yes (1) | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (1) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | 0 | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (1) | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | Yes (1) | ProfessionalFundraisingInd |
| Fundraising Activities | Yes (1) | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | 0 | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | Yes (1) | DisregardedEntityInd |
| Related Entity | 0 | RelatedEntityInd |
| Related Organization Ctrl Ent | 0 | RelatedOrganizationCtrlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 96 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 69 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | Yes (1) | QuidProQuoContributionsInd |
| Quid Pro Quo Contri Discl | Yes (1) | QuidProQuoContriDisclInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 11 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 11 | IndependentVotingMemberCnt |
| Family Or Business Rln | 0 | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | GA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | HI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ME | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MO | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | ND | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Other Website | Yes (X) | OtherWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | JONATHAN WALSH | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 3015569385 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 22512 GATEWAY CENTER DRIVE | AddressLine1Txt |
| City | CLARKSBURG | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 20871 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (23 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|
| PATRICIA M STEWART | ||||||||
| CHAIR | 10.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| CECILIA ARRADAZA | ||||||||
| VICE CHAIR | 6.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| SCOTT KAISER MD DIRECTOR | ||||||||
| UNTIL 10/2023 THEN SECRETARY | 6.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| EDWARD FINLEY | ||||||||
| TREASURER - UNTIL 12/2023 | 8.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| SHAWA GOTTLIEB | ||||||||
| TREASURER - AS OF 12/2023 | 6.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| PAUL CAMPBELL | ||||||||
| DIRECTOR | 5.00 | Yes (X) | $0 | $0 | $0 | |||
| HERBERT L DRAYTON III | ||||||||
| DIRECTOR - AS OF 6/2023 | 5.00 | Yes (X) | $0 | $0 | $0 | |||
| DANA GRIFFIN | ||||||||
| DIRECTOR | 5.00 | Yes (X) | $0 | $0 | $0 | |||
| TONYA MATTHEWS PHD | ||||||||
| DIRECTOR | 5.00 | Yes (X) | $0 | $0 | $0 | |||
| ANN SECLOW | ||||||||
| DIRECTOR | 5.00 | Yes (X) | $0 | $0 | $0 | |||
| JAN M STOUFFER PHD | ||||||||
| DIRECTOR | 6.00 | Yes (X) | $0 | $0 | $0 | |||
| THOMAS F FREDDO OD PHD | ||||||||
| DIRECTOR - AS OF 6/2023 | 5.00 | Yes (X) | $0 | $0 | $0 | |||
| STACY PAGOS HALLER | ||||||||
| PRESIDENT/CEO | 45.00 | Yes (X) | $410,407 | $0 | $57,485 | |||
| NANCY LYNN | ||||||||
| SR. VP STRATEGIC PARTNERSHIPS | 45.00 | $261,148 | $0 | $61,492 | Yes (X) | |||
| R BRIAN ELDERTON | ||||||||
| SR. VP, DEVELOPMENT | 45.00 | $253,852 | $0 | $48,328 | Yes (X) | |||
| DAVID F MARKS CPA CMA | ||||||||
| VP, FINANCE & ADMIN TILL 10/2023 | 45.00 | $156,941 | $0 | $54,684 | Yes (X) | |||
| DIANE BOVENKAMP PHD | ||||||||
| VP, SCIENTIFIC AFFAIRS | 45.00 | $190,217 | $0 | $22,240 | Yes (X) | |||
| KACI BAEZ | ||||||||
| VP, INTEGRATED MKTING & COMM. | 45.00 | $172,602 | $0 | $26,649 | Yes (X) | |||
| AYO ABRAHAM CPA CGMA | ||||||||
| CONTROLLER UNTIL 8/2023 | 40.00 | $138,926 | $0 | $21,356 | Yes (X) | |||
| JEFFREY HONAKER | ||||||||
| SR. MGR. OPS AND BUILDING | 40.00 | $112,157 | $0 | $44,404 | Yes (X) | |||
| LISA MORGAN | ||||||||
| DIRECTOR OF ANNUAL GIVING | 40.00 | $128,316 | $0 | $33,647 | Yes (X) | |||
| PREETI SUBRAMANIAN PHD DIR | ||||||||
| OF SCIENT. PROGRAMS, VISION SCIENCE | 40.00 | $135,115 | $0 | $15,657 | Yes (X) | |||
| SHARYN ROSSI PHD DIR OF | ||||||||
| SCIENT. PROGRAMS, NEUROSCIENCE | 40.00 | $125,361 | $0 | $43,832 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $2,085,042 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $429,774 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 11 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| RKD GROUP | |||||
| 35 PARKWOOD DRIVE SUITE 160 | HOPKINTON | MA | 01748 | PUBLIC AWARENESS CONSULTING & MATERIALS | $9,668,749 |
| ADSTRA LLC | |||||
| 750 COLLEGE ROAD EAST STE 201 | PRINCETON | NJ | 08540 | MAIL LIST RENTAL | $1,382,715 |
| ALLEGIANCE GROUP | |||||
| 2300 CLARENDON BLVD SUITE 925 | ARLINGTON | VA | 22201 | ONLINE PUBLIC AWARENESS CONSULTING | $622,303 |
| THREESIXTYEIGHT | |||||
| 212 S 14TH STREET SUITE B | BATON ROUGE | LA | 70802 | ONLINE MARKETING CONSULTING | $352,659 |
| DATA MANAGEMENT INC | |||||
| 160 STONE STREET | STONEVILLE | NC | 27048 | DATABASE MANAGEMENT | $273,722 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 17 | CntrctRcvdGreaterThan100KCnt |
| Federated Campaigns | $144,175 | FederatedCampaignsAmt |
| Fundraising | $250,290 | FundraisingAmt |
| All Other Contributions | $42,978,738 | AllOtherContributionsAmt |
| Noncash Contributions | $87,848 | NoncashContributionsAmt |
| Total Contributions | $43,373,203 | TotalContributionsAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $798,230 | TotalRevenueColumnAmt |
| Exclusion | $798,230 | ExclusionAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $453,517 | TotalRevenueColumnAmt |
| Exclusion | $453,517 | ExclusionAmt |
Gross Rents GrossRentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $658,538 | RealAmt |
Less Rental Expenses LessRentalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $190,252 | RealAmt |
Rental Income Or Loss RentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $468,286 | RealAmt |
Net Rental Income Or Loss NetRentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $468,286 | TotalRevenueColumnAmt |
| Exclusion | $468,286 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $54,207,314 | SecuritiesAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $50,303,280 | SecuritiesAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $3,904,034 | SecuritiesAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $3,904,034 | TotalRevenueColumnAmt |
| Exclusion | $3,904,034 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $64,000 | FundraisingGrossIncomeAmt |
| Contri Rpt Fundraising Event | $250,290 | ContriRptFundraisingEventAmt |
| Fundraising Direct Expenses | $398,470 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$334,470 | TotalRevenueColumnAmt |
| Exclusion | -$334,470 | ExclusionAmt |
Other Revenue Misc OtherRevenueMiscGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | OTHER INCOME | Desc |
| Business | 900099 | BusinessCd |
| Total Revenue Column | $70 | TotalRevenueColumnAmt |
| Exclusion | $70 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $70 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $48,662,870 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $5,289,667 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $7,478,202 | TotalAmt |
| Program Services | $7,478,202 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,225,891 | TotalAmt |
| Program Services | $3,225,891 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,673,188 | TotalAmt |
| Program Services | $1,075,672 | ProgramServicesAmt |
| Management And General | $284,661 | ManagementAndGeneralAmt |
| Fundraising | $312,855 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,983,008 | TotalAmt |
| Program Services | $1,920,677 | ProgramServicesAmt |
| Management And General | $1,463,124 | ManagementAndGeneralAmt |
| Fundraising | $599,207 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $219,886 | TotalAmt |
| Program Services | $105,789 | ProgramServicesAmt |
| Management And General | $83,997 | ManagementAndGeneralAmt |
| Fundraising | $30,100 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $663,765 | TotalAmt |
| Program Services | $344,647 | ProgramServicesAmt |
| Management And General | $218,083 | ManagementAndGeneralAmt |
| Fundraising | $101,035 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $336,824 | TotalAmt |
| Program Services | $177,521 | ProgramServicesAmt |
| Management And General | $105,575 | ManagementAndGeneralAmt |
| Fundraising | $53,728 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $75,990 | TotalAmt |
| Program Services | $38,302 | ProgramServicesAmt |
| Management And General | $27,836 | ManagementAndGeneralAmt |
| Fundraising | $9,852 | FundraisingAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $81,938 | TotalAmt |
| Program Services | $41,300 | ProgramServicesAmt |
| Management And General | $30,015 | ManagementAndGeneralAmt |
| Fundraising | $10,623 | FundraisingAmt |
Fees For Services Prof Fundraising FeesForServicesProfFundraising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $952,781 | TotalAmt |
| Fundraising | $952,781 | FundraisingAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $273,750 | TotalAmt |
| Management And General | $273,750 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,594,728 | TotalAmt |
| Program Services | $1,474,665 | ProgramServicesAmt |
| Management And General | $120,063 | ManagementAndGeneralAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,079,425 | TotalAmt |
| Program Services | $596,196 | ProgramServicesAmt |
| Fundraising | $483,229 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $970,677 | TotalAmt |
| Program Services | $337,172 | ProgramServicesAmt |
| Management And General | $453,550 | ManagementAndGeneralAmt |
| Fundraising | $179,955 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $831,368 | TotalAmt |
| Program Services | $533,749 | ProgramServicesAmt |
| Management And General | $195,594 | ManagementAndGeneralAmt |
| Fundraising | $102,025 | FundraisingAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $450,550 | TotalAmt |
| Program Services | $263,051 | ProgramServicesAmt |
| Management And General | $141,343 | ManagementAndGeneralAmt |
| Fundraising | $46,156 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $333,566 | TotalAmt |
| Program Services | $258,676 | ProgramServicesAmt |
| Management And General | $36,837 | ManagementAndGeneralAmt |
| Fundraising | $38,053 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,447,219 | TotalAmt |
| Program Services | $1,387,712 | ProgramServicesAmt |
| Management And General | $15,731 | ManagementAndGeneralAmt |
| Fundraising | $43,776 | FundraisingAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $335,181 | TotalAmt |
| Management And General | $335,181 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $611,056 | TotalAmt |
| Program Services | $324,229 | ProgramServicesAmt |
| Management And General | $207,081 | ManagementAndGeneralAmt |
| Fundraising | $79,746 | FundraisingAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $89,387 | TotalAmt |
| Program Services | $38,558 | ProgramServicesAmt |
| Management And General | $29,158 | ManagementAndGeneralAmt |
| Fundraising | $21,671 | FundraisingAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| PUB. AWARENESS POSTAGE | $8,449,837 | $4,024,943 | $525,953 | $3,898,941 |
| PUB. AWARENESS PRINTING | $7,323,026 | $3,404,221 | $456,105 | $3,462,700 |
| PUB. AWARENESS COMP. | $2,088,455 | $996,071 | $108,658 | $983,726 |
| LIST RENTAL | $1,647,708 | $754,899 | $102,155 | $790,654 |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $46,217,406 | TotalAmt |
| Program Services | $28,802,143 | ProgramServicesAmt |
| Management And General | $5,214,450 | ManagementAndGeneralAmt |
| Fundraising | $12,200,813 | FundraisingAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Joint Costs | Yes (X) | JointCostsInd |
Total Joint Costs TotalJointCostsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $18,479,592 | TotalAmt |
| Program Services | $7,878,147 | ProgramServicesAmt |
| Management And General | $1,129,037 | ManagementAndGeneralAmt |
| Fundraising | $9,472,408 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $205,653 | BOYAmt |
| EOY | $829,628 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,889,254 | BOYAmt |
| EOY | $8,516,562 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,522,988 | BOYAmt |
| EOY | $6,199,054 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $165,585 | BOYAmt |
| EOY | $23,832 | EOYAmt |
Inventories For Sale Or Use InventoriesForSaleOrUseGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $51,738 | BOYAmt |
| EOY | $28,325 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $50,244 | BOYAmt |
| EOY | $998,282 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $13,397,952 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $5,550,668 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $8,128,279 | BOYAmt |
| EOY | $7,847,284 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $39,542,541 | BOYAmt |
| EOY | $31,237,150 | EOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| EOY | $7,784,535 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $70,195 | BOYAmt |
| EOY | $0 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $58,626,477 | BOYAmt |
| EOY | $63,464,652 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,112,727 | BOYAmt |
| EOY | $2,580,327 | EOYAmt |
Grants Payable GrantsPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $33,119,925 | BOYAmt |
| EOY | $24,991,458 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $116,500 | BOYAmt |
| EOY | $0 | EOYAmt |
Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $9,000,000 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $715,557 | BOYAmt |
| EOY | $674,130 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $35,064,709 | BOYAmt |
| EOY | $37,245,915 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $10,360,299 | BOYAmt |
| EOY | $12,270,789 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $13,201,469 | BOYAmt |
| EOY | $13,947,948 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $23,561,768 | BOYAmt |
| EOY | $26,218,737 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $58,626,477 | BOYAmt |
| EOY | $63,464,652 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | Yes (X) | InfoInScheduleOPartXIInd |
| Reconcilation Revenue Expnss | $2,445,464 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | -$94,500 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | $306,005 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | 0 | FederalGrantAuditRequiredInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $35,740,875 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $48,502,473 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $46,522,410 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $43,451,535 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $43,373,203 | CurrentTaxYearAmt |
| Total | $217,590,496 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $35,740,875 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $48,502,473 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $46,522,410 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $43,451,535 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $43,373,203 | CurrentTaxYearAmt |
| Total | $217,590,496 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $431,008 | SubstantialContributorsTotAmt |
| Public Support Total170 | $217,159,488 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $2,176,998 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,887,633 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $2,074,361 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $1,972,869 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $1,910,285 | CurrentTaxYearAmt |
| Total | $10,022,146 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus2 Years | $7,500 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year | $70 | CurrentTaxYearAmt |
| Total | $7,570 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $227,620,212 | TotalSupportAmt |
| Public Support CY170 | 0.95400 | PublicSupportCY170Pct |
| Public Support PY170 | 0.95300 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Form990 Schedule A Part VI Form990ScheduleAPartVIGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: | FormAndLineReferenceDesc |
| Explanation | SAVINGS BOND PAYOUT - 2021 AMOUNT: $ 7,500. MISCELLANEOUS - 2023 AMOUNT: $ 70. | ExplanationTxt |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
Total Grassroots Lobbying TotalGrassrootsLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Total Direct Lobbying TotalDirectLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Total Lobbying Expend TotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Other Exempt Purpose Expend OtherExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $45,579,597 | FilingOrganizationsTotalAmt |
Total Exempt Purpose Expend TotalExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $45,579,597 | FilingOrganizationsTotalAmt |
Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $1,000,000 | FilingOrganizationsTotalAmt |
Grassroots Nontaxable GrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $250,000 | FilingOrganizationsTotalAmt |
Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $1,000,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $1,000,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $1,000,000 | CurrentYearMinus1Amt |
| Current Year | $1,000,000 | CurrentYearAmt |
| Total | $4,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Lobbying Ceiling | $6,000,000 | LobbyingCeilingAmt |
Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $250,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $250,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $250,000 | CurrentYearMinus1Amt |
| Current Year | $250,000 | CurrentYearAmt |
| Total | $1,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grassroots Ceiling | $1,500,000 | GrassrootsCeilingAmt |
Schedule D IRS990ScheduleD
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $310,022 | BeginningYearBalanceAmt |
| Contributions | $23,199 | ContributionsAmt |
| Investment Earnings Or Losses | -$23,199 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $23,199 | OtherExpendituresAmt |
| End Year Balance | $286,823 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $325,000 | BeginningYearBalanceAmt |
| Contributions | $14,978 | ContributionsAmt |
| Investment Earnings Or Losses | -$14,978 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $14,978 | OtherExpendituresAmt |
| End Year Balance | $310,022 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $302,000 | BeginningYearBalanceAmt |
| Contributions | $13,634 | ContributionsAmt |
| Investment Earnings Or Losses | $23,000 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $13,634 | OtherExpendituresAmt |
| End Year Balance | $325,000 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $302,000 | BeginningYearBalanceAmt |
| Contributions | $14,744 | ContributionsAmt |
| Other Expenditures | $14,744 | OtherExpendituresAmt |
| End Year Balance | $302,000 | EndYearBalanceAmt |
CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $302,000 | BeginningYearBalanceAmt |
| Contributions | $14,778 | ContributionsAmt |
| Other Expenditures | $14,778 | OtherExpendituresAmt |
| End Year Balance | $302,000 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Designated Balance EOY | 0.00000 | BoardDesignatedBalanceEOYPct |
| Prmnnt Endowment Balance EOY | 1.00000 | PrmnntEndowmentBalanceEOYPct |
| Term Endowment Balance EOY | 0.00000 | TermEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | Yes (1) | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | 0 | EndowmentsHeldRelatedOrgInd |
Land LandGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Investment Cost Or Other Basis | $2,800,000 | InvestmentCostOrOtherBasisAmt |
| Other Cost Or Other Basis | $1,147,363 | OtherCostOrOtherBasisAmt |
| Book Value | $3,947,363 | BookValueAmt |
Buildings BuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Investment Cost Or Other Basis | $1,629,400 | InvestmentCostOrOtherBasisAmt |
| Other Cost Or Other Basis | $5,422,721 | OtherCostOrOtherBasisAmt |
| Depreciation | $4,283,276 | DepreciationAmt |
| Book Value | $2,768,845 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $2,181,715 | OtherCostOrOtherBasisAmt |
| Depreciation | $1,068,672 | DepreciationAmt |
| Book Value | $1,113,043 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $216,753 | OtherCostOrOtherBasisAmt |
| Depreciation | $198,720 | DepreciationAmt |
| Book Value | $18,033 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $7,847,284 | TotalBookValueLandBuildingsAmt |
Other Securities OtherSecuritiesGrp (2 entries)
| DescDesc | Book ValueBookValueAmt | Method ValuationMethodValuationCd |
|---|---|---|
| MAKENA PERPETUAL PRIVATE EQUITY FUND | $3,717,628 | F |
| MAKENA PERPETUAL VENTURE CAPITAL FUND | $4,066,907 | F |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Securities | $7,784,535 | TotalBookValueSecuritiesAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp (3 entries)
| DescDesc | AmtAmt |
|---|---|
| CHARITABLE GIFT ANNUITIES | $536,350 |
| CAPITAL LEASE OBLIGATIONS | $112,780 |
| RENTAL DEPOSITS | $25,000 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $674,130 | TotalLiabilityAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $73,443,828 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | -$94,500 | NetUnrealizedGainsInvstAmt |
| Donated Services And Use Fclts | $24,713,985 | DonatedServicesAndUseFcltsAmt |
| Recoveries Prior Year Grants | $435,223 | RecoveriesPriorYearGrantsAmt |
| Revenue Not Reported | $25,054,708 | RevenueNotReportedAmt |
| Revenue Subtotal | $48,389,120 | RevenueSubtotalAmt |
| Investment Expenses Not Incld | $273,750 | InvestmentExpensesNotIncldAmt |
| Revenue Not Reported Fincl Stmt | $273,750 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $48,662,870 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $70,786,859 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $24,713,985 | DonatedServicesUseFcltsAmt |
| Expenses Not Reported | $24,713,985 | ExpensesNotReportedAmt |
| Expenses Subtotal | $46,072,874 | ExpensesSubtotalAmt |
| Investment Expenses Not Incld2 | $273,750 | InvestmentExpensesNotIncld2Amt |
| Other Expenses Not Included | -$129,218 | OtherExpensesNotIncludedAmt |
| Expenses Not Rpt Fincl Stmt | $144,532 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $46,217,406 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (3 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART V, LINE 4: | THE EARNINGS ON THIS ENDOWMENT ARE AVAILABLE FOR THE ALZHEIMER'S DISEASE RESEARCH PROGRAM, ARE RECORDED AS TEMPORARILY RESTRICTED INVESTMENT INCOME, AND ARE RELEASED AS SPENT. |
| PART X, LINE 2: | BRIGHTFOCUS PERFORMED AN EVALUATION OF UNCERTAINTY IN INCOME TAXES FOR THE YEAR ENDED MARCH 31, 2024, AND DETERMINED THAT THERE WERE NO MATTERS THAT WOULD REQUIRE RECOGNITION IN THE CONSOLIDATED FINANCIAL STATEMENTS OR THAT MAY HAVE ANY EFFECT ON ITS TAX-EXEMPT STATUS. |
| PART XII, LINE 4B - OTHER ADJUSTMENTS: | CHANGE IN PRESENT VALUE OF GRANTS -129,218. |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (3 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|
| EAST ASIA AND THE PACIFIC | 0 | 0 | GRANTMAKING | $499,924 |
| EUROPE | 0 | 0 | GRANTMAKING | $2,067,294 |
| NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES | 0 | 0 | GRANTMAKING | $658,672 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Subtotal Spent | $3,225,890 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $3,225,890 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (14 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Non Cash AssistanceNonCashAssistanceAmt |
|---|---|---|---|---|
| NORTH AMERICA | MACULAR DEGENERATION RESEARCH BY BRITTANY CARR, PHD, ENTITLED: (M2024011N) | $450,000 | WIRE TRANSFER | $0 |
| EUROPE (INCLUDING ICELAND AND GREENLAND) | MACULAR DEGENERATION RESEARCH BY MAXIMILIAN PFAU, PHD, ENTITLED: (M2024009N) | $330,400 | WIRE TRANSFER | $0 |
| EUROPE (INCLUDING ICELAND AND GREENLAND) | ALZHEIMER'S DISEASE RESEARCH BY MARIA LLORENS-MARTN, PHD, ENTITLED: (A2024021S) | $300,000 | WIRE TRANSFER | $0 |
| EUROPE (INCLUDING ICELAND AND GREENLAND) | ALZHEIMER'S DISEASE RESEARCH BY EMANUELA PASCIUTO, PHD, ENTITLED: (A2024020S) | $300,000 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | ALZHEIMER'S DISEASE RESEARCH BY GUOJUN BU, PHD, ENTITLED: (A2024019S) | $300,000 | WIRE TRANSFER | $0 |
| EUROPE (INCLUDING ICELAND AND GREENLAND) | ALZHEIMER'S DISEASE RESEARCH BY RAFFAELLA NATIVIO, PHD, ENTITLED: (A2024018S) | $299,943 | WIRE TRANSFER | $0 |
| EUROPE (INCLUDING ICELAND AND GREENLAND) | BIRAX RESEARCH FUNDING, ENTITLED: (CA2023002) | $202,027 | WIRE TRANSFER | $0 |
| NORTH AMERICA | ALZHEIMER'S DISEASE RESEARCH BY JULIE OTTOY, PHD, ENTITLED: (A2024012F) | $200,000 | WIRE TRANSFER | $0 |
| EUROPE (INCLUDING ICELAND AND GREENLAND) | ALZHEIMER'S DISEASE RESEARCH BY GEMMA SALVAD, PHD, ENTITLED: (A2024007F) | $200,000 | WIRE TRANSFER | $0 |
| EUROPE (INCLUDING ICELAND AND GREENLAND) | ALZHEIMER'S DISEASE RESEARCH BY HELENA GELLERSEN, PHD, ENTITLED: (A2024013F) | $199,967 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | NATIONAL GLAUCOMA RESEARCH BY JENNIFER FAN GASKIN, MBCHB, MD, FRANZCO, ENTITLED: (G2024011S) | $199,924 | WIRE TRANSFER | $0 |
| EUROPE (INCLUDING ICELAND AND GREENLAND) | ALZHEIMER'S DISEASE RESEARCH BY MARTIN J. DAHL, PHD, PHD, ENTITLED: (A2024006F) | $199,130 | WIRE TRANSFER | $0 |
| EUROPE (INCLUDING ICELAND AND GREENLAND) | NATIONAL GLAUCOMA RESEARCH BY DARRYL OVERBY, PHD, ENTITLED: (CG2020003) | $35,828 | WIRE TRANSFER | $0 |
| NORTH AMERICA | MIND AND SIGHT DISEASES RESEARCH FUNDING, ENTITLED: (CA2023003) | $6,672 | WIRE TRANSFER | $0 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 14 | Total501c3OrgCnt |
| Total Other Org | 0 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | 0 | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (4 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 2: | BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE, INCLUDING IMAGING, MOLECULAR BIOLOGY AND SIGNALING PATHWAYS, CELL BIOLOGY, ANGIOGENESIS, BIOCHEMISTRY, NEUROSCIENCE, AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE SCIENTIFIC AFFAIRS COMMITTEE OF THE BOARD OF DIRECTORS. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS. AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CATEGORY NORMALIZED CITATION IMPACT ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO AN UNBIASED COMPARISON OF IMPACT PERFORMANCE VERSUS THE WORLD AVERAGE. BRIGHTFOCUS-SUPPORTED PUBLICATIONS WERE RECENTLY CITED AT 2 TIMES THE FREQUENCY OF THE WORLD AVERAGE. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES ADDITIONAL GRANTS FOR FOLLOW-ON PROJECTS SPAWNED BY THE BRIGHTFOCUS GRANT, WITH VALUES UP TO 10 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT. BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES, AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGH THE BRIGHTFOCUS FOUNDATION WEBSITE AND WITHIN THE SCIENTIFIC PROGRESS REPORTS, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO THAT BRIGHTFOCUS CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS. |
| PART I, LINE 3: | BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS. |
| PART II, LINE 1: | BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS. |
| PART II, LINE 1, COLUMN (D) | REGION: EUROPE (INCLUDING ICELAND AND GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MARTIN J. DAHL, PHD, ENTITLED: (A2024006F) SHINING A LIGHT ON HOW EARLY TAU-RELATED BRAIN CHANGES AFFECT MEMORY LOSS. INVESTIGATOR'S SUMMARY: THIS PROJECT SPOTLIGHTS PREVIOUSLY UNDERSTUDIED BRAIN REGIONSTINY NUCLEI IN THE BRAINSTEMTHAT ARE THE STARTING POINT OF ALZHEIMER'S-RELATED TAU ACCUMULATION AND INVESTIGATES HOW THEIR CHANGES CONTRIBUTE TO MEMORY LOSS. USING INNOVATIVE BRAIN IMAGING TECHNIQUES, BLOOD-BASED BIOMARKERS, AND MEMORY ASSESSMENTS COLLECTED OVER A DECADE FROM A LARGE NUMBER OF PARTICIPANTS, THIS PROJECT IMPROVES OUR UNDERSTANDING OF THE TIME COURSE OF NEURAL CHANGES IN LATER LIFE AND THEIR MECHANISTIC ROLE IN THE EARLIEST STAGES OF ALZHEIMER'S DEVELOPMENT. GRANT AWARDED: $199,130, MAX PLANCK INSTITUTE FOR HUMAN DEVELOPMENT, BERLIN, GERMANY. REGION: EUROPE (INCLUDING ICELAND AND GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY GEMMA SALVAD, PHD, ENTITLED: (A2024007F) STAGING ALZHEIMER'S DISEASE WITH BLOOD-BASED MEASURES. INVESTIGATOR'S SUMMARY: RESEARCHERS WILL DEVELOP A STAGING MODEL FOR ALZHEIMER'S DISEASE BASED ON PLASMA BIOMARKERS, WHICH WILL HELP CHARACTERIZE PEOPLE ACROSS THE DIFFERENT PHASES OF THE DISEASE. THE STUDY WILL ALSO INVESTIGATE HOW MULTIPLE PROTEIN LEVELS CHANGE ACROSS THESE STAGES TO BETTER UNDERSTAND THE COMPLEX BIOLOGICAL PROCESSES THAT OCCUR DURING THE DISEASE. RESEARCHERS ENVISION THAT THE STAGING MODEL MAY HELP DECIDE, IN AN EASY AND COST-EFFECTIVE WAY, WHO WOULD BENEFIT FROM A TREATMENT AGAINST ALZHEIMER'S DISEASE AND PERFORM A MORE PERSONALIZED MANAGEMENT OF THE INDIVIDUAL. STUDYING PROTEIN CHANGES MAY ALSO UNVEIL NEW DRUG TARGETS FOR ALZHEIMER'S. GRANT AWARDED: $200,000, LUND UNIVERSITY, LUND, SWEDEN. REGION: NORTH AMERICA (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JULIE OTTOY, PHD, ENTITLED: (A2024012F) THE ROLE OF BRAIN VASCULAR-IMMUNE PROCESSES IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: DAMAGE TO THE BRAIN'S BLOOD VESSELS CAN TRIPLE THE RISK OF DEVELOPING ALZHEIMER'S DISEASE, AND OVERACTIVE IMMUNE CELLS MAY FURTHER EXACERBATE THIS DAMAGE. HERE, RESEARCHERS WILL STUDY HOW THESE VASCULAR-IMMUNE RESPONSES AFFECT ALZHEIMER'S PROGRESSION BY ANALYZING BRAIN SCANS AND BLOOD SAMPLES FROM 500+ INDIVIDUALS OVER TIME. STUDY OUTCOMES WILL PRESENT A UNIQUE AND MORE DETAILED PICTURE OF KEY AND UNDERSTUDIED MECHANISMS DRIVING ALZHEIMER'S, THEREBY OPENING NEW PERSPECTIVES ON THE DEVELOPMENT OF PERSONALIZED BIOMARKERS AND TREATMENT STRATEGIES THAT TARGET THE INTERFACE BETWEEN THE VASCULAR SYSTEM, BRAIN IMMUNE CELLS, AND ALZHEIMER'S. GRANT AWARDED: $200,000, SUNNYBROOK RESEARCH INSTITUTE, TORONTO, CANADA. REGION: EUROPE (INCLUDING ICELAND AND GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY HELENA GELLERSEN, PHD, ENTITLED: (A2024013F) IDENTIFYING NEW MEMORY AND BRAIN MARKERS FOR EARLY ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: DESPITE NEWLY AVAILABLE TREATMENTS FOR ALZHEIMER'S DISEASE, DEMENTIA SUBTYPE SPECIFICITY IS IMPORTANT TO DETERMINE PRIOR TO TREATMENT TO ENSURE SAFE AND EFFICACIOUS OUTCOMES. OPTIMIZED COGNITIVE ASSESSMENTS AND IMAGING BIOMARKERS ARE ALSO ESSENTIAL FOR EARLY DETECTION AND TO MONITOR DISEASE PROGRESSION. THIS PROJECT WILL ADDRESS THESE CHALLENGES BY DEVELOPING NEW COGNITIVE AND NEURAL MARKERS SENSITIVE TO THE EARLY EFFECTS OF ALZHEIMER'S. THESE MARKERS CAN BE USED TO SCREEN FOR SUBTLE MEMORY CHANGES, CLASSIFY BY SUBTYPE, AND IDENTIFY SIGNATURES OF HEALTHY BRAIN FUNCTION THAT CAN CLARIFY MECHANISMS OF DISEASE-MODIFYING EFFECTS ON MEMORY IN EARLY-PHASE CLINICAL TRIALS. GRANT AWARDED: $199,967, GERMAN CENTER FOR NEURODEGENERATIVE DISEASES, MAGDEBURG, GERMANY. REGION: EUROPE (INCLUDING ICELAND AND GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY RAFFAELLA NATIVIO, PHD, ENTITLED: (A2024018S) UNCOVERING HOW GENE REGULATORS PROTECT NEURONS AGAINST ALZHEIMER'S. INVESTIGATOR'S SUMMARY: THIS STUDY WILL FOCUS ON UNDERSTANDING HOW EPIGENETIC FACTORS, ESPECIALLY TRANSCRIPTIONAL REPRESSORS, INFLUENCE GENE EXPRESSION IN NEURONS AND CONTRIBUTE TO ALZHEIMER'S DISEASE. THE RESEARCH AIMS TO IDENTIFY HOW THESE TRANSCRIPTIONAL REPRESSORS PROTECT NEURONS FROM ALZHEIMER'S-RELATED STRESS, POTENTIALLY LEADING TO NEW TREATMENTS FOR ENHANCING BRAIN RESILIENCE AGAINST ALZHEIMER'S. GRANT AWARDED: $299,943, IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY, AND MEDICINE, LONDON, UNITED KINGDOM. REGION: EAST ASIA AND THE PACIFIC (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY GUOJUN BU, PHD, ENTITLED: (A2024019S) PERIPHERAL APOE IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: DESPITE ENCOURAGING NEWS ON ANTI-AMYLOID DRUGS, RESEARCHERS ARE STILL FAR FROM DEVELOPING SAFE AND EFFECTIVE THERAPIES TO PREVENT OR CURE ALZHEIMER'S DISEASE. THE APOE GENE IS A STRONG RISK FACTOR, WITH APOE4 INCREASING AND APOE2 REDUCING RISK. THIS PROJECT WILL STUDY THE PROTECTIVE EFFECT OF APOE2 USING NEW MODEL SYSTEMS AND ADVANCED TECHNOLOGIES. THESE STUDIES WILL ADDRESS HOW APOE2 IN THE BLOOD AFFECTS BRAIN COGNITION AND ALZHEIMER'S DISEASE PATHOLOGY. OUTCOMES FROM THESE STUDIES SHOULD PROVIDE NEW KNOWLEDGE ON HOW DIFFERENT FORMS OF APOE AFFECT ALZHEIMER'S DISEASE AND HOW APOE EXPRESSED IN THE PERIPHERY AFFECTS BRAIN FUNCTION AND NEUROPATHOLOGY. MORE IMPORTANTLY, THE STUDY OUTCOMES WILL GUIDE US TO DESIGN APOE-TARGETED THERAPIES TO DELAY THE ONSET OR SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE. GRANT AWARDED: $300,000, THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, KOWLOON, HONG KONG. REGION: EUROPE (INCLUDING ICELAND AND GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY EMANUELA PASCIUTO, PHD, ENTITLED: (A2024020S) MODULATION OF MICROGLIA-T CELLS CROSS TALK IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: WHILE MICROGLIA ARE IN THE SPOTLIGHT, RESEARCHERS KNOW LITTLE ABOUT HOW ADAPTIVE IMMUNE CELLS INTERACT WITH ALZHEIMER'S AMYLOID PLAQUES. MHCII IS A MICROGLIA-ASSOCIATED ALZHEIMER'S RISK GENE THAT FUNCTIONS TO MEDIATE INTERACTION WITH T CELLS. THE RELEVANCE OF THE MICROGLIA-T CELL INTERACTION IN ALZHEIMER'S IS UNKNOWN. TO STUDY THE CONTRIBUTION OF THIS INTERACTION TO ALZHEIMER'S PATHOLOGY, DR. PASCIUTO AND HER TEAM WILL USE GENETIC MODELS TO MANIPULATE MHC II EXPRESSION IN MICE AND TEST EFFICACY OF T CELL-BASED IMMUNOTHERAPY IN ALZHEIMER'S MICE LACKING MHCII. DR. PASCIUTO'S RESEARCH WILL EXTEND THE CURRENT KNOWLEDGE OF HOW THE IMMUNE SYSTEM CHANGES IN ALZHEIMER'S DISEASE. BY UNCOVERING THESE MECHANISMS, THIS STUDY BUILDS THE BASIS TOWARD MORE PRECISE THERAPIES THAT TARGET THE IMMUNE SYSTEM TO PROTECT AGAINST THE PROGRESSION OF ALZHEIMER'S. ADDITIONALLY, THIS RESEARCH WILL ESTABLISH HOW THE ALZHEIMER'S RISK GENE MHCII INFLUENCES THE DEVELOPMENT OF ALZHEIMER'S AND THE RESPONSE TO POTENTIAL IMMUNE-BASED TREATMENTS, OFFERING HOPE FOR MORE PERSONALIZED APPROACHES TO COMBATING THE DISEASE. GRANT AWARDED: $300,000, FLANDERS INSTITUTE FOR BIOTECHNOLOGY, ANTWERP, BELGIUM. REGION: EUROPE (INCLUDING ICELAND AND GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MARIA LLORENS-MARTN, PHD, ENTITLED: (A2024021S) DOES ALZHEIMERS DISEASE ACCELERATE BRAIN AGING? INVESTIGATOR'S SUMMARY: THE HIPPOCAMPUS, A BRAIN REGION CRUCIAL FOR LEARNING AND MEMORY, GENERATES NEW NEURONS THROUGHOUT LIFE. THIS PROCESS IS DAMAGED IN PEOPLE WITH ALZHEIMER'S DISEASE, BUT THE CAUSE OF THESE ALTERATIONS IS UNKNOWN. DR. LLORENS-MARTN AND HER TEAM WILL USE HIGH-QUALITY HUMAN BRAIN SAMPLES AND CUTTING-EDGE GENOMIC AND MICROSCOPY METHODOLOGIES TO ASSESS THE TOXICITY OF THE ENVIRONMENT THAT SURROUNDS NEW NEURONS. STUDY FINDINGS WILL IDENTIFY NOVEL MECHANISMS RESPONSIBLE FOR HIPPOCAMPAL PERTURBATION IN ALZHEIMER'S AND GENERATE NOVEL RESOURCES THAT ALLOW FASTER AND MORE ACCURATE DIAGNOSIS OF THIS CONDITION. GRANT AWARDED: $300,000, SPANISH NATIONAL RESEARCH COUNCIL, MADRID, SPAIN. REGION: EUROPE (INCLUDING ICELAND AND GREENLAND) (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY MAXIMILIAN PFAU, PHD, ENTITLED: (M2024009N) INNOVATIVE VISION TESTS TO MONITOR TREATMENT EFFECTS IN AMD. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) CAUSES DEVASTATING VISION LOSS OVER TIME. HOWEVER, BEST-CORRECTED VISUAL ACUITYTHE MOST COMMON VISION TESTDOES NOT REVEAL DYSFUNCTION IN EARLY AMD. THUS, CLINICAL TRIALS FOCUS MOSTLY ON LATE AMD, DESPITE THE LIMITED TREATMENT POTENTIAL. THIS PROJECT WILL ESTABLISH VISION TESTS THAT EVALUATE DARK ADAPTATION FOLLOWING EXPOSURE TO BRIGHT LIGHT. USING RETINA TRACKING, RESEARCHERS WILL TEST SMALL RETINAL REGIONS PRONE TO SUBTLE PHOTORECEPTOR DYSFUNCTION IN AN UNPRECEDENTEDLY ACCURATE MANNER, MAKING DISEASE PROGRESSION MEASURABLE AT THE EARLIEST STAGE. GRANT AWARDED: $330,400, INSTITUTE OF MOLECULAR AND CLINICAL OPHTHALMOLOGY BASEL, BASEL, SWITZERLAND. |
Schedule G IRS990ScheduleG
| Field | Value | IRS element (for citing) |
|---|---|---|
| Mail Solicitations | Yes (X) | MailSolicitationsInd |
| Email Solicitations | Yes (X) | EmailSolicitationsInd |
| Solicitation Of Non Govt Grants | Yes (X) | SolicitationOfNonGovtGrantsInd |
| Special Fundraising Events | Yes (X) | SpecialFundraisingEventsInd |
| Agrmt Prof Fundraising Acty | Yes (1) | AgrmtProfFundraisingActyInd |
Fundraiser Activity Info FundraiserActivityInfoGrp (2 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | ActivityActivityTxt | Fundraiser Control Of FundsFundraiserControlOfFundsInd | Gross ReceiptsGrossReceiptsAmt | Retained By ContractorRetainedByContractorAmt | Net To OrganizationNetToOrganizationAmt |
|---|---|---|---|---|---|---|---|---|
| RKD GROUP | ||||||||
| 35 PARKWOOD DRIVE STE 160 | HOPKINTON | MA | 01748 | FUNDRAISING AND COMMUNICATIONS CONSULTANT | 0 | $30,452,088 | $499,942 | $29,952,146 |
| BEACONFIRE REDENGINE | ||||||||
| 2300 CLARENDON BLVD STE 925 | ARLINGTON | VA | 22201 | FUNDRAISING AND COMMUNICATIONS CONSULTANT | 0 | $2,368,623 | $452,839 | $1,915,784 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Gross Receipts | $32,820,711 | TotalGrossReceiptsAmt |
| Total Retained By Contractors | $952,781 | TotalRetainedByContractorsAmt |
| Total Net To Organization | $31,867,930 | TotalNetToOrganizationAmt |
| Licensed States | AK | LicensedStatesCd |
| Licensed States | AL | LicensedStatesCd |
| Licensed States | AR | LicensedStatesCd |
| Licensed States | AZ | LicensedStatesCd |
| Licensed States | CA | LicensedStatesCd |
| Licensed States | CO | LicensedStatesCd |
| Licensed States | CT | LicensedStatesCd |
| Licensed States | DC | LicensedStatesCd |
| Licensed States | FL | LicensedStatesCd |
| Licensed States | GA | LicensedStatesCd |
| Licensed States | HI | LicensedStatesCd |
| Licensed States | IL | LicensedStatesCd |
| Licensed States | KS | LicensedStatesCd |
| Licensed States | KY | LicensedStatesCd |
| Licensed States | LA | LicensedStatesCd |
| Licensed States | MA | LicensedStatesCd |
| Licensed States | MD | LicensedStatesCd |
| Licensed States | ME | LicensedStatesCd |
| Licensed States | MI | LicensedStatesCd |
| Licensed States | MN | LicensedStatesCd |
| Licensed States | MO | LicensedStatesCd |
| Licensed States | MS | LicensedStatesCd |
| Licensed States | NC | LicensedStatesCd |
| Licensed States | ND | LicensedStatesCd |
| Licensed States | NH | LicensedStatesCd |
| Licensed States | NJ | LicensedStatesCd |
| Licensed States | NM | LicensedStatesCd |
| Licensed States | NV | LicensedStatesCd |
| Licensed States | NY | LicensedStatesCd |
| Licensed States | OH | LicensedStatesCd |
| Licensed States | OK | LicensedStatesCd |
| Licensed States | OR | LicensedStatesCd |
| Licensed States | PA | LicensedStatesCd |
| Licensed States | RI | LicensedStatesCd |
| Licensed States | SC | LicensedStatesCd |
| Licensed States | TN | LicensedStatesCd |
| Licensed States | UT | LicensedStatesCd |
| Licensed States | VA | LicensedStatesCd |
| Licensed States | WA | LicensedStatesCd |
| Licensed States | WI | LicensedStatesCd |
| Licensed States | WV | LicensedStatesCd |
Fundraising Event Information FundraisingEventInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Event1 | BRIGHTFOCUS 50TH ANNIVERSARY CELEBR | Event1Nm |
| Gross Receipts Event1 | $314,290 | GrossReceiptsEvent1Amt |
| Charitable Contri Event1 | $250,290 | CharitableContriEvent1Amt |
| Gross Revenue Event1 | $64,000 | GrossRevenueEvent1Amt |
| Rent Facility Costs Event1 | $17,300 | RentFacilityCostsEvent1Amt |
| Food And Beverage Event1 | $149,677 | FoodAndBeverageEvent1Amt |
| Entertainment Event1 | $157,317 | EntertainmentEvent1Amt |
| Other Direct Expenses Event1 | $74,176 | OtherDirectExpensesEvent1Amt |
| Gross Receipts Total | $314,290 | GrossReceiptsTotalAmt |
| Charitable Contributions Tot | $250,290 | CharitableContributionsTotAmt |
| Gross Revenue Total Events | $64,000 | GrossRevenueTotalEventsAmt |
| Rent Fclty Costs Total Events | $17,300 | RentFcltyCostsTotalEventsAmt |
| Food And Beverage Total Events | $149,677 | FoodAndBeverageTotalEventsAmt |
| Entertainment Total Events | $157,317 | EntertainmentTotalEventsAmt |
| Oth Direct Expnss Total Events | $74,176 | OthDirectExpnssTotalEventsAmt |
| Direct Expense Summary Events | $398,470 | DirectExpenseSummaryEventsAmt |
| Net Income Summary | -$334,470 | NetIncomeSummaryAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE G, PART I, LINE 2B, COLUMN (V) | FormAndLineReferenceDesc |
| Explanation | IN THE CONTRACT WITH RKD GROUP, THE MANAGEMENT FEES ARE FIXED AMOUNTS PER MONTH FOR IN-SCOPE SERVICES THAT TOTALS $1,151,196 PER YEAR OF WHICH $606,941 HAS BEEN ALLOCATED UNDER PART IX, LINE 11(G) TO PROGRAM AND MANAGEMENT AND ARE NOT CONSIDERED TO BE THE PROFESSIONAL FUNDRAISING CONSULTANT FEE. | ExplanationTxt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (35 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Non Cash AssistanceNonCashAssistanceAmt | Purpose Of GrantPurposeOfGrantTxt | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|---|
| BOSTON CHILDREN'S HOSPITAL | |||||||||
| 300 LONGWOOD AVENUE | BOSTON | MA | 02115 | 042774441 | 501(C)(3) | $200,000 | $0 | MACULAR DEGENERATION RESEARCH BY NEETU KUSHWAH, PHD, ENTITLED: (M2024002F) | |
| COLUMBIA UNIVERSITY | |||||||||
| 535 W 116TH STREET | NEW YORK | NY | 10027 | 135598093 | 501(C)(3) | $166,667 | $0 | NATIONAL GLAUCOMA RESEARCH BY SIMON JOHN, PHD, ENTITLED: (CG2020004) | |
| DUKE UNIVERSITY | |||||||||
| 2200 WEST MAIN STREET SUITE 820 | DURHAM | NC | 27705 | 560532129 | 501(C)(3) | $52,325 | $0 | NATIONAL GLAUCOMA RESEARCH BY W. DANIEL STAMER, PHD, ENTITLED: (CG2020002) | |
| EMORY UNIVERSITY | |||||||||
| SCHOOL OF NURSING 1520 CLIFTON RD | ATLANTA | GA | 30322 | 580566256 | 501(C)(3) | $300,000 | $0 | ALZHEIMER'S DISEASE RESEARCH BY BRITTANY BUTTS, PHD, ENTITLED: (A2024024S) | |
| GEORGIA INSTITUTE OF TECHNOLOGY | |||||||||
| FERST DRIVE ROOM 230 | ATLANTA | GA | 30332 | 586002023 | 501(C)(3) | $85,561 | $0 | NATIONAL GLAUCOMA RESEARCH BY C. ROSS ETHIER, PHD, ENTITLED: (CG2020001) | |
| GEORGIA TECH RESEARCH CORPORATION | |||||||||
| BIOMEDICAL ENGINEERING 315 FERST | ATLANTA | GA | 30332 | 580603146 | 501(C)(3) | $150,000 | $0 | NATIONAL GLAUCOMA RESEARCH BY HAIYAN LI, PHD, ENTITLED: (G2024003F) | DRIVE |
| GEORGIA TECH RESEARCH CORPORATION | |||||||||
| SCHOOL OF CHEMISTRY AND | ATLANTA | GA | 30332 | 580603146 | 501(C)(3) | $150,000 | $0 | NATIONAL GLAUCOMA RESEARCH BY HANNAH YOUNGBLOOD, PHD, ENTITLED: (G2024001F) | BIOCHEMISTRY 311 FERST DRIVE |
| HEBREW REHABILITATION CENTER | |||||||||
| 1200 CENTRE STREET | ROSLINDALE | MA | 02131 | 042104298 | 501(C)(3) | $297,336 | $0 | ALZHEIMER'S DISEASE RESEARCH BY DAVIDE CAPPON, PHD, ENTITLED: (A2024027S) | |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | |||||||||
| GENETICS AND GENOMIC SCIENCES 1425 | NEW YORK | NY | 10029 | 136171197 | 501(C)(3) | $300,000 | $0 | ALZHEIMER'S DISEASE RESEARCH BY ANNA PODLESNY-DRABINIOK, PHD, ENTITLED: (A2024025S) | MADISON AVENUE |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | |||||||||
| NEUROSCIENCE 1425 MADISON AVENUE | NEW YORK | NY | 10029 | 136171197 | 501(C)(3) | $193,526 | $0 | ALZHEIMER'S DISEASE RESEARCH BY TATSUHIKO NAITO, MD, PHD, ENTITLED: (A2024004F) | ICAHN 10-52 |
| INDIANA UNIVERSITY | |||||||||
| MEDICAL AND MOLECULAR GENETICS 320 | INDIANAPOLIS | IN | 46202 | 356001673 | 501(C)(3) | $150,000 | $0 | NATIONAL GLAUCOMA RESEARCH BY SHRUTI PATIL, PHD, ENTITLED: (G2024002F) | W 15TH ST NB 408 |
| JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | |||||||||
| DEPARTMENT OF OPHTHALMOLOGY 400 N | BALTIMORE | MD | 21231 | 520595110 | 501(C)(3) | $200,000 | $0 | MACULAR DEGENERATION RESEARCH BY KRISHNA SINGH, PHD, ENTITLED: (M2024003F) | BROADWAY |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 55 FRUIT ST | BOSTON | MA | 02145 | 042697983 | 501(C)(3) | $200,000 | $0 | ALZHEIMER'S DISEASE RESEARCH BY MD JOYNAL ABEDIN, PHD, ENTITLED: (A2024010F) | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 114 16TH STREET | BOSTON | MA | 02145 | 042697983 | 501(C)(3) | $300,000 | $0 | ALZHEIMER'S DISEASE RESEARCH BY JAEHONG SUH, PHD, ENTITLED: (A2024022S) | |
| MAYO CLINIC JACKSONVILLE | |||||||||
| 4500 SAN PABLO ROAD | JACKSONVILLE | FL | 32224 | 593337028 | 501(C)(3) | $299,997 | $0 | ALZHEIMER'S DISEASE RESEARCH BY MERCEDES PRUDENCIO, PHD, ENTITLED: (A2024017S) | |
| OREGON HEALTH & SCIENCE UNIVERSITY | |||||||||
| 3181 SW SAM JACKSON PARK ROAD | PORTLAND | OR | 97239 | 931176109 | 501(C)(3) | $200,000 | $0 | ALZHEIMER'S DISEASE RESEARCH BY PAULA SANCHEZ-MOLINA, PHD, ENTITLED: (A2024011F) | |
| OREGON HEALTH & SCIENCE UNIVERSITY | |||||||||
| 3181 SW SAM JACKSON PARK ROAD | PORTLAND | OR | 97239 | 931176109 | 501(C)(3) | $200,000 | $0 | NATIONAL GLAUCOMA RESEARCH BY DIANA LOZANO, PHD, ENTITLED: (G2024009S) | |
| SAINT LOUIS UNIVERSITY | |||||||||
| INTERNAL MEDICINE 1402 S GRAND BLVD | ST LOUIS | MO | 63104 | 430654872 | 501(C)(3) | $300,000 | $0 | ALZHEIMER'S DISEASE RESEARCH BY ANDREW D. NGUYEN, PHD, ENTITLED: (A2024028S) | |
| SCHEPENS EYE RESEARCH INSTITUTE INC | |||||||||
| 20 STANIFORD STREET | BOSTON | MA | 02114 | 042129889 | 501(C)(3) | $200,000 | $0 | MACULAR DEGENERATION RESEARCH BY SHINTARO SHIRAHAMA, MD, PHD, ENTITLED: (M2024004F) | |
| STANFORD UNIVERSITY | |||||||||
| NEUROLOGY 1201 WELCH RD | PALO ALTO | CA | 94305 | 941156365 | 501(C)(3) | $200,000 | $0 | ALZHEIMER'S DISEASE RESEARCH BY HANNAH ENNERFELT, PHD, ENTITLED: (A2024005F) | |
| STANFORD UNIVERSITY | |||||||||
| 2452 WATSON CT | PALO ALTO | CA | 94305 | 941156365 | 501(C)(3) | $62,531 | $0 | NATIONAL GLAUCOMA RESEARCH BY JEFFREY GOLDBERG, PHD, ENTITLED: (CG2022001) | |
| SUNY UPSTATE MEDICAL UNIVERSITY | |||||||||
| 505 IRVING AVE NEUROSCIENCE | SYRACUSE | NY | 13210 | 141368361 | 501(C)(3) | $200,000 | $0 | NATIONAL GLAUCOMA RESEARCH BY SAMUEL HERBERG, PHD, ENTITLED: (G2024006S) | RESEARCH BLDG ROOM4609 |
| THE PENNSYLVANIA STATE UNIVERSITY COLLEGE OF MEDICINE | |||||||||
| CELLULAR AND MOLECULAR PHYSIOLOGY | HERSHEY | PA | 17033 | 246000376 | 501(C)(3) | $200,000 | $0 | MACULAR DEGENERATION RESEARCH BY SANDEEP MOOTHEDATH SUBRAHMANIAN, PHD, ENTITLED: (M2024006F) | 500 UNIVERSITY DRIVE |
| TUFTS UNIVERSITY | |||||||||
| NEUROSCIENCE 136 HARRISON AVENUE | BOSTON | MA | 02111 | 042103634 | 501(C)(3) | $300,000 | $0 | ALZHEIMER'S DISEASE RESEARCH BY GIUSEPPINA TESCO, MD, PHD, ENTITLED: (A2024016S) | |
| UNIVERSITY OF CALIFORNIA BERKELEY | |||||||||
| 1608 FOURTH STREET | BERKELEY | CA | 94710 | 946002123 | 501(C)(3) | $200,000 | $0 | ALZHEIMER'S DISEASE RESEARCH BY SANKALP SHUKLA, PHD, ENTITLED: (A2024008F) | |
| UNIVERSITY OF CALIFORNIA SAN FRANCISCO | |||||||||
| OPHTHALMOLOGY 490 ILLINOIS STREET | SAN FRANCISCO | CA | 94143 | 946036493 | 501(C)(3) | $150,000 | $0 | NATIONAL GLAUCOMA RESEARCH BY MENGYA ZHAO, PHD, ENTITLED: (G2024005F) | 4TH FLOOR |
| UNIVERSITY OF CALIFORNIA SAN FRANCISCO | |||||||||
| 513 PARNASSUS AVE | SAN FRANCISCO | CA | 94143 | 946036493 | 501(C)(3) | $200,000 | $0 | ALZHEIMER'S DISEASE RESEARCH BY SARAH KAUFMAN, MD, PHD, ENTITLED: (A2024001F) | |
| UNIVERSITY OF COLORADO | |||||||||
| 1800 GRANT STREET | DENVER | CO | 80203 | 846000555 | 501(C)(3) | $428,935 | $0 | MACULAR DEGENERATION RESEARCH BY MIGUEL FLORES-BELIVER, PHD, ENTITLED: (M2024008N) | |
| UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC | |||||||||
| 310 E CAMPUS ROAD | ATHENS | GA | 30602 | 581353149 | 501(C)(3) | $449,985 | $0 | MACULAR DEGENERATION RESEARCH BY HEIKE KROEGER, PHD, ENTITLED: (M2024010N) | |
| UNIVERSITY OF MICHIGAN MEDICAL CENTER | |||||||||
| KELLOGG EYE CENTER DEPARTMENT OF | ANN ARBOR | MI | 48105 | 386006309 | 501(C)(3) | $200,000 | $0 | MACULAR DEGENERATION RESEARCH BY JOHN HAN, PHD, ENTITLED: (M2024001F) | OPHTHALMOLOGY 1000 WALL STREET |
| UNIVERSITY OF PITTSBURGH | |||||||||
| OPHTHALMOLOGY 1622 LOCUST ST | PITTSBURGH | PA | 15260 | 250965591 | 501(C)(3) | $150,000 | $0 | NATIONAL GLAUCOMA RESEARCH BY BINGRUI WANG, PHD, ENTITLED: (G2024004F) | |
| UNIVERSITY OF VIRGINIA | |||||||||
| 1001 N EMMET STREET | CHARLOTTESVILLE | VA | 22903 | 546001796 | 501(C)(3) | $200,000 | $0 | NATIONAL GLAUCOMA RESEARCH BY XIARONG LIU, PHD, ENTITLED: (G2024008S) | |
| UNIVERSITY OF WASHINGTON | |||||||||
| BIOLOGICAL STRUCTURE 4333 BROOKLYN | SEATTLE | WA | 98195 | 916001537 | 501(C)(3) | $191,339 | $0 | MACULAR DEGENERATION RESEARCH BY JULIETTE WOHLSCHLEGEL, PHD, ENTITLED: (M2024005F) | AVE NE BOX 359472 |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| PSYCHIATRY 4370 DUNCAN AVENUE | ST LOUIS | MO | 63130 | 430653611 | 501(C)(3) | $200,000 | $0 | ALZHEIMER'S DISEASE RESEARCH BY DANIRA TORAL-RIOS, PHD, ENTITLED: (A2024002F) | |
| WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY | |||||||||
| 1300 YORK AVE | NEW YORK | NY | 10065 | 131623978 | C CORP | $200,000 | $0 | ALZHEIMER'S DISEASE RESEARCH BY WENHUI QU, PHD, ENTITLED: (A2024003F) | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 34 | Total501c3OrgCnt |
| Total Other Org | 1 | TotalOtherOrgCnt |
Supplemental Information Detail SupplementalInformationDetail (5 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 2: | BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE, INCLUDING IMAGING, MOLECULAR BIOLOGY AND SIGNALING PATHWAYS, CELL BIOLOGY, ANGIOGENESIS, BIOCHEMISTRY, NEUROSCIENCE, AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE SCIENTIFIC AFFAIRS COMMITTEE OF THE BOARD OF DIRECTORS. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS. AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CATEGORY NORMALIZED CITATION IMPACT ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO AN UNBIASED COMPARISON OF IMPACT PERFORMANCE VERSUS THE WORLD AVERAGE. BRIGHTFOCUS-SUPPORTED PUBLICATIONS WERE RECENTLY CITED AT 2 TIMES THE FREQUENCY OF THE WORLD AVERAGE. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES ADDITIONAL GRANTS FOR FOLLOW-ON PROJECTS SPAWNED BY THE BRIGHTFOCUS GRANT, WITH VALUES UP TO 10 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT. BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES, AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGH THE BRIGHTFOCUS FOUNDATION WEBSITE AND WITHIN THE SCIENTIFIC PROGRESS REPORTS, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO THAT BRIGHTFOCUS CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS. |
| PART II, LINE 1(H) | NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SARAH KAUFMAN, MD, PHD, ENTITLED: (A2024001F) IDENTIFYING MECHANISMS OF TAU AGGREGATION & TOXICITY ACROSS TAUOPATHIES. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA FEATURE THE ACCUMULATION OF MISFOLDED, AGGREGATED TAU PROTEIN IN NEURONS THAT ARE LOST EARLY IN THE COURSE OF THESE DISEASES. THE MECHANISMS THAT UNDERLIE TAU MISFOLDING AND ACCUMULATION, AND ITS ASSOCIATED NEUROTOXICITY, ARE NOT KNOWN. THIS PROJECT EMPLOYS WHOLE-GENOME SCREENING TECHNIQUES TO IDENTIFY THE CELLULAR PATHWAYS THAT REGULATE TAU AGGREGATION AND TOXICITY IN HUMAN-INDUCED PLURIPOTENT STEM CELL-DERIVED NEURONS. THIS WORK WILL PROVIDE CRITICAL INSIGHT INTO TAU-ASSOCIATED DISEASE MECHANISMS AND IDENTIFY POTENTIAL THERAPEUTIC TARGETS FOR ALZHEIMER'S AND FRONTOTEMPORAL DEMENTIA. NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY IN ST. LOUIS (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DANIRA TORAL-RIOS, PHD, ENTITLED: (A2024002F) OXYSTEROLS IN INNATE AND ADAPTIVE IMMUNITY IN A TAUOPATHY MOUSE MODEL. INVESTIGATOR'S SUMMARY: NEURONAL LOSS IN ALZHEIMER'S DISEASE IS LINKED TO BRAIN INFILTRATION OF BLOOD-DERIVED IMMUNE CELLS IN A NEUROTOXIC CASCADE OF TAU PROTEIN ACCUMULATION AND INFLAMMATION IN THE BRAIN. PRELIMINARY STUDIES SHOW EVIDENCE FOR ALTERED BRAIN CHOLESTEROL METABOLISM IN MEDIATING TAU PATHOLOGY AND INFILTRATION OF BLOOD IMMUNE CELLS INTO THE BRAIN. THIS PROJECT AIMS TO INVESTIGATE THIS PATHWAY WITH THE LONG-TERM GOAL OF PHARMACOLOGICAL INTERVENTION TO BLOCK NEURONAL LOSS IN ALZHEIMER'S. NAME OF ORGANIZATION OR GOVERNMENT: WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY WENHUI QU, PHD, ENTITLED: (A2024003F) UNLOCKING TAU'S SECRETS: HUMAN BRAIN CELLS IN THE LIVING MOUSE BRAIN. INVESTIGATOR'S SUMMARY: DR. QU HAS PIONEERED MODELING TAU BUILDUP IN HUMAN NEURONS USING DIFFERENT TYPES OF NEURAL CELLS FROM STEM CELLS DERIVED FROM SKIN BIOPSY. THIS STUDY PROPOSES TRANSPLANTING BOTH HUMAN NEURONS AND MICROGLIATHE BRAIN'S IMMUNE CELLSINTO MOUSE BRAINS TO GENERATE A GROUNDBREAKING CHIMERA HUMAN-MOUSE MODEL THAT DEVELOPS TAU ACCUMULATION. USING THIS MODEL, THE STUDY WILL ALSO EXAMINE HOW HUMAN SPECIFIC MOLECULAR PATHWAYS AFFECT THE DISEASE'S PROGRESSION. THIS RESEARCH COULD LEAD TO BREAKTHROUGHS IN UNDERSTANDING AND TREATING ALZHEIMER'S AND OTHER TAU-RELATED DISEASES. NAME OF ORGANIZATION OR GOVERNMENT: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY TATSUHIKO NAITO, MD, PHD, ENTITLED: (A2024004F) DECODING ALZHEIMER'S DISEASE GENOMES WITH DEEP LEARNING. INVESTIGATOR'S SUMMARY: DR. NAITO'S RESEARCH AIMS TO UNRAVEL THE GENETIC COMPLEXITIES OF ALZHEIMER'S DISEASE. THIS PROJECT HAS TWO PRIMARY OBJECTIVES: TO DEVELOP A PIPELINE TO PREDICT THE IMPACT OF GENETIC MUTATIONS ON RNA PROCESSING IN BRAIN CELLS BY STATE-OF-THE-ART MACHINE-LEARNING TECHNOLOGIES AND TO INVESTIGATE HOW GENETIC MUTATIONS HAVE AN IMPACT ON INDIVIDUALS WITH ALZHEIMER'S VIA RNA PROCESSING BY APPLYING THIS PIPELINE TO HUGE GENOMIC DATA. A BETTER UNDERSTANDING OF GENETIC ASSOCIATIONS OF ALZHEIMER'S WILL HELP IN DEVELOPING NEW TREATMENTS AND IDENTIFYING BIOMARKERS. NAME OF ORGANIZATION OR GOVERNMENT: STANFORD UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY HANNAH ENNERFELT, PHD, ENTITLED: (A2024005F) THE ROLE OF THE IMMUNE SYSTEM IN DRIVING COGNITIVE DECLINE. INVESTIGATOR'S SUMMARY: DURING AGING AND ALZHEIMER'S DISEASE, CERTAIN INFLAMMATORY RESPONSES REGULATED BY THE IMMUNE SYSTEM FURTHER EXACERBATE THE DISEASE AND CONTRIBUTE TO IMPAIRED COGNITION AND MEMORY. THIS STUDY FOCUSES ON DELINEATING THE MACHINERY NECESSARY FOR IMMUNE CELLS TO AMPLIFY DAMAGING INFLAMMATION IN THE BODY AND, ULTIMATELY, THE BRAIN. USING A NOVEL METHOD TO TARGET A SPECIFIC IMMUNE CELL MECHANISM, DR. ENNERFELT AND COLLEAGUES WILL ASSESS HOW IMPEDING ITS ASSOCIATED INFLAMMATORY PATHWAYS CAN CURB COGNITIVE DECLINE AND ALZHEIMER'S PROGRESSION. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, BERKELEY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SANKALP SHUKLA, PHD, ENTITLED: (A2024008F) UNDERSTANDING THE ROLE OF PROTEIN CLUMPS ON MEMBRANE IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: NEURODEGENERATIVE DISEASES LIKE ALZHEIMER'S DISEASE ARE CAUSED BY THE BUILDUP OF CLUMPS OF PROTEINS THAT SPREAD FROM ONE PART OF THE BRAIN TO ANOTHER, CAUSING PROGRESSIVE BRAIN DAMAGE. THESE PROTEIN CLUMPS CAN INTERACT AND DISRUPT THE MEMBRANES RESPONSIBLE FOR CONTAINING AND DESTROYING THEM, CAUSING PROTEIN CLUMP LEAKAGE AND SPREAD. THIS PROJECT AIMS TO UNDERSTAND THE UNDERLYING CAUSE OF THIS MEMBRANE LEAKAGE FOR THE DEVELOPMENT OF THERAPIES TO COUNTERACT PROTEIN CLUMP ESCAPE BY PROMOTING THE REPAIR OF THE MEMBRANES DAMAGED BY THESE PROTEIN CLUMPS. NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MD JOYNAL ABEDIN, PHD, ENTITLED: (A2024010F) THE EFFECT OF ALZHEIMER'S DISEASE ON NEURONS ACROSS THE SLEEP/WAKE CYCLE. INVESTIGATOR'S SUMMARY: IN ALZHEIMER'S DISEASE, BUILDUP OF AMYLOID BETA (A) PROTEIN CAN RESULT IN SLEEP DISTURBANCES. DR. ABEDIN AND HIS TEAM WILL INVESTIGATE THE ACTIVITY OF SPECIFIC NEURONAL TYPES IN A GENETICALLY ENGINEERED MOUSE MODEL OF ALZHEIMER'S DISEASE TO UNDERSTAND HOW A AFFECTS NEURONAL ACTIVITY DURING THE SLEEP/WAKE CYCLE. THIS RESEARCH COULD PAVE THE WAY FOR THERAPEUTIC DEVELOPMENT AIMED AT RESTORING ABNORMAL NEURONAL ACTIVITY AND POTENTIALLY LEADING TO A CURE FOR ALZHEIMER'S DISEASE. NAME OF ORGANIZATION OR GOVERNMENT: OREGON HEALTH & SCIENCE UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY PAULA SANCHEZ-MOLINA, PHD, ENTITLED: (A2024011F) ROLE OF THE IMMUNE SYSTEM IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE HAS TRADITIONALLY BEEN CONSIDERED A NEURONAL PATHOLOGY, BUT NOW IT IS KNOWN THAT A SPECIFIC TYPE OF BRAIN IMMUNE CELL, CALLED MICROGLIA, PLAYS A CRUCIAL ROLE IN THE PATHOGENESIS OF THE DISEASE. THIS PROJECT AIMS TO UNDERSTAND HOW IMMUNE CELLS FROM THE BLOOD IMPACT MICROGLIA AND CONTRIBUTE TO THE DEVELOPMENT OF ALZHEIMER'S DISEASE. THIS PROJECT WILL USE HUMAN SAMPLES, ENABLING RESEARCHERS TO OBTAIN POTENTIAL TRANSLATIONAL RESULTS FOR THE CLINIC. THE CHARACTERIZATION AND VALIDATION OF A PERIPHERAL IMMUNE MECHANISM THAT CONTRIBUTES TO ALZHEIMER'S PATHOLOGY COULD OFFER IMPORTANT BIOMARKERS FOR DISEASE DIAGNOSIS AND THE DESIGN OF NEW THERAPIES. NAME OF ORGANIZATION OR GOVERNMENT: TUFTS UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY GIUSEPPINA TESCO, MD, PHD, ENTITLED: (A2024016S) ROLE OF GGA3 IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: DR. TESCO'S LAB RECENTLY FOUND A NOVEL GENETIC VARIANT ASSOCIATED WITH LATE-ONSET ALZHEIMER'S DISEASE IN AFRICAN AMERICAN FAMILIES, CALLED GGA3 . HER RESEARCH PREVIOUSLY DEMONSTRATED THAT GGA3 PLAYS A CRITICAL ROLE IN THE TRANSPORT AND REGULATION OF BACE1, A KEY ENZYME RESPONSIBLE FOR AMYLOID-BETA PRODUCTION. THE STUDY AIMS TO DETERMINE HOW THIS NOVEL GENETIC VARIANT LEADS TO ALZHEIMER'S DISEASE. RESULTS MAY CONTRIBUTE TO A BETTER UNDERSTANDING OF GENETIC RISK FACTORS IN THE AFRICAN AMERICAN POPULATION, WHICH IS CURRENTLY UNDERSTUDIED. NAME OF ORGANIZATION OR GOVERNMENT: MAYO CLINIC JACKSONVILLE (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MERCEDES PRUDENCIO, PHD, ENTITLED: (A2024017S) UNDERSTANDING THE CONTRIBUTION OF TDP-43 LOSS OF FUNCTION IN AD. INVESTIGATOR'S SUMMARY: TDP-43 PROTEINS ABNORMALLY ACCUMULATE IN THE BRAIN OF UP TO 70% OF PEOPLE WITH ALZHEIMER'S DISEASE AND ARE CHARACTERIZED BY WORSE MEMORY AND GREATER BRAIN ATROPHY COMPARED TO THOSE WITH ALZHEIMER'S LACKING TDP-43 PATHOLOGY. THIS PROPOSAL AIMS TO CHARACTERIZE THE ROLE OF TDP-43 DYSFUNCTION IN THE PATHOGENESIS OF ALZHEIMER'S BY EVALUATING: 1) WHETHER TDP-43 DYSFUNCTION EXACERBATES BEHAVIOR AND PATHOLOGICAL ALZHEIMER'S PHENOTYPES, AS WELL AS INDUCES NEURONAL LOSS IN AN ALZHEIMER'S MOUSE MODEL, AND 2) THE RELATIONSHIPS BETWEEN ALZHEIMER'S PATHOLOGIES AND TDP-43 DYSFUNCTION IN ALZHEIMER'S HUMAN BRAINS. THESE STUDIES ARE EXPECTED TO ALSO HIGHLIGHT THE IMPORTANCE OF TDP-43 PATHOLOGY IN THERAPEUTIC TARGET AND BIOMARKER DESIGN AND IN PARTICIPANT EVALUATIONS DURING CLINICAL TRIALS. |
| PART II, LINE 1(H) CONTINUED | NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JAEHONG SUH, PHD, ENTITLED: (A2024022S) INCREASE OF BRAIN ADAM10 EXPRESSION AS ALZHEIMER'S DISEASE THERAPEUTIC. INVESTIGATOR'S SUMMARY: ADAM10 IS AN ENZYME THAT PREVENTS THE GENERATION OF AMYLOID-BETA, THE MAIN COMPONENT OF SENILE PLAQUES IN ALZHEIMER'S DISEASE BRAINS. PREVIOUS STUDIES CONSISTENTLY SHOWED THAT LOSS OF ADAM10 FUNCTION INCREASES ALZHEIMER'S RISK, SUGGESTING THAT INCREASING ADAM10 EXPRESSION CAN BE A PROMISING THERAPEUTIC TARGET. THIS STUDY WILL TEST IF BRAIN-SELECTIVE MODULATION OF ADAM10 EXPRESSION AFFECTS ALZHEIMER'S PATHOGENESIS AND DEVELOP AN EXPERIMENTAL ANTISENSE OLIGONUCLEOTIDE DRUG THAT INCREASES ADAM10 EXPRESSION FOR ALZHEIMER'S TREATMENT. IF SUCCESSFUL, DR. SUH AND OTHERS COULD SCREEN FDA-APPROVED DRUGS OR OTHER MEDICINAL LIBRARIES TO IDENTIFY SMALL MOLECULE COMPOUNDS THAT INCREASE ADAM10 EXPRESSION AND DEVELOP THEM AS ALZHEIMER'S DRUGS. IN ADDITION, ADAM10 ANTISENSE OLIGONUCLEOTIDES IDENTIFIED FROM THE PROPOSED STUDY CAN BE OPTIMIZED FOR HUMAN SEQUENCES AND FURTHER TESTED AND DEVELOPED FOR ALZHEIMER'S TREATMENT. NAME OF ORGANIZATION OR GOVERNMENT: EMORY UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY BRITTANY BUTTS, PHD, ENTITLED: (A2024024S) ALZHEIMER'S DISEASE RISK AND IMMUNE FUNCTION IN HEART DISEASE. INVESTIGATOR'S SUMMARY: THIS STUDY EXPLORES HOW THE IMMUNE SYSTEM RELATES TO MEMORY, COGNITION, AND ALZHEIMER'S RISK IN MIDDLE-AGED ADULTS WITH HEART CONDITIONS. AS HEART PROBLEMS SURGE IN THE UNDER-65 POPULATION, THE CONNECTION TO COGNITIVE DECLINE AND ALZHEIMER'S REMAINS UNCLEAR. SURVEYS, BLOOD TESTS, AND MEMORY ASSESSMENTS WILL BE USED TO BETTER UNDERSTAND HOW FACTORS LIKE HIGH BLOOD PRESSURE AFFECT COGNITION AND MAY ELEVATE ALZHEIMER'S RISK. INSIGHTS INTO HEART HEALTH, IMMUNITY, AND ALZHEIMER'S CAN BENEFIT AT-RISK INDIVIDUALS AND SHAPE FUTURE TREATMENTS. NAME OF ORGANIZATION OR GOVERNMENT: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ANNA PODLESNY-DRABINIOK, PHD, ENTITLED: (A2024025S) MICROGLIAL REPROGRAMMING IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: HUMAN GENETIC STUDIES IMPLICATE MICROGLIA, THE BRAIN'S "TRASH COLLECTOR" CELLS, AS KEY PLAYERS IN ALZHEIMER'S DISEASE. DR. PODLESNY-DRABINIOK AND COLLEAGUES NOMINATED CANDIDATE FACTORS THAT MAY BOOST THE ABILITY OF MICROGLIA TO DISPOSE OF THE WASTE THAT ACCUMULATES DURING ALZHEIMER'S. HERE, THE STUDY AIMS TO VALIDATE COMPUTATIONAL PREDICTIONS AND CHARACTERIZE THE ROLE OF TWO CANDIDATE FACTORS IN HUMAN MICROGLIA AT BASELINE AND IN THE CONTEXT OF AMYLOIDS. RESEARCHERS WILL ALSO TARGET THESE FACTORS IN MICROGLIA DERIVED FROM PEOPLE CARRYING TWO COPIES OF APOE4 TO HELP THESE CELLS OVERCOME THE DEFICITS ASSOCIATED WITH THIS MAJOR GENETIC FACTOR FOR ALZHEIMER'S. DR. PODLESNY-DRABINIOK'S RESEARCH HOLDS THE POTENTIAL TO EXPLORE NOVEL THERAPEUTIC STRATEGIES AIMING TO INDUCE WASTE CLEARANCE PROCESSES IN MICROGLIA. NAME OF ORGANIZATION OR GOVERNMENT: HEBREW REHABILITATION CENTER (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DAVIDE CAPPON, PHD, ENTITLED: (A2024027S) SYMPTOM-SPECIFIC NEUROSTIMULATION FOR DEMENTIA. INVESTIGATOR'S SUMMARY: THIS PROJECT WILL COMBINE TWO TYPES OF TRANSCRANIAL ELECTRICAL STIMULATION, A NONINVASIVE TECHNOLOGY THAT ALLOWS FOR THE MODULATION OF BRAIN NETWORK ACTIVITY TO ADDRESS DEPRESSIVE AND MEMORY SYMPTOMS IN OLDER ADULTS WITH DEPRESSION AND ALZHEIMER'S DEMENTIA. BY USING CUTTING-EDGE TECHNOLOGY TO STUDY THE ELECTRICAL FIELDS GENERATED IN THE TARGETED BRAIN CIRCUITS AND DELIVERING THE INTERVENTION AT HOME, THIS PROJECT WILL HELP DEVELOP A SCALABLE, ACCESSIBLE, NONINVASIVE INTERVENTION WITH THE GREATEST IMPACT ON ALLEVIATING DEPRESSION AND ALZHEIMER'S SYMPTOMS. NAME OF ORGANIZATION OR GOVERNMENT: SAINT LOUIS UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ANDREW D. NGUYEN, PHD, ENTITLED: (A2024028S) PROGRANULIN AS A POTENTIAL THERAPEUTIC TARGET FOR ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: PREVIOUS STUDIES SUGGEST THAT PROGRANULIN CONFERS A PROTECTIVE EFFECT ON ALZHEIMER'S DISEASE IN MOUSE MODELS AND IN HUMANS, BUT SEVERAL IMPORTANT GAPS IN KNOWLEDGE EXIST. THIS PROJECT AIMS TO DETERMINE HOW PROGRANULIN EXERTS ITS EFFECTS IN THE CENTRAL NERVOUS SYSTEM TO ENHANCE MEMORY AND TO TEST IF PHARMACOLOGICALLY INCREASING PROGRANULIN LEVELS CAN PROTECT AGAINST ALZHEIMER'S DISEASE. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF MICHIGAN MEDICAL CENTER (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY JOHN HAN, PHD, ENTITLED: (M2024001F) TARGETING LIPID STORAGE FOR TREATING AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) IS CHARACTERIZED BY THE BUILDUP OF FATTY DEPOSITS OUTSIDE A CELL LAYER IN THE BACK OF THE EYE CALLED THE RETINAL PIGMENT EPITHELIUM (RPE). AS PART OF ITS NORMAL FUNCTION, THE RPE CONSUMES ENORMOUS AMOUNTS OF FAT EACH DAY, AND THIS FAT IS TEMPORARILY STORED INSIDE THE CELL IN SPHERES CALLED LIPID DROPLETS. THE RESEARCHERS' GOAL IS TO UNDERSTAND HOW THE RPE FORMS LIPID DROPLETS AND MANIPULATE THOSE LIPID DROPLETS IN SUCH A WAY THAT LESS FAT IS SECRETED FROM THE RPE TO FORM THE TOXIC FATTY DEPOSITS OUTSIDE THE CELL THAT CHARACTERIZE AMD. TARGETING ENZYMES GOVERNING LIPID DROPLET FORMATION AND DEGRADATION HAS BECOME A VIABLE THERAPEUTIC STRATEGY IN OTHER DISEASES. RPE LIPID DROPLETS MAY BE CRITICAL GUARDIANS AGAINST THE ONSET OF AMD. LIPID DROPLETS ARE HIGHLY DRUGGABLE, WITH AVAILABLE SMALL MOLECULES THAT ARE HIGHLY SPECIFIC TO TARGET ENZYMES REQUIRED FOR LIPID DROPLET FORMATION AND LIPID RELEASE, PROVIDING AN INNOVATIVE NEW THERAPEUTIC APPROACH FOR AMD. NAME OF ORGANIZATION OR GOVERNMENT: BOSTON CHILDREN'S HOSPITAL (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY NEETU KUSHWAH, PHD, ENTITLED: (M2024002F) ROLE OF NUCLEAR RECEPTOR RORA IN LIPID DYSREGULATION. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) IS A LEADING CAUSE OF BLINDNESS AMONG PEOPLE AGED 60 AND OLDER. IT IS A MULTIFACTORIAL DISEASE INVOLVING MULTIPLE CELLULAR PATHWAYS, AMONG WHICH LIPID DYSREGULATION AND INFLAMMATION ARE MAJOR PATHOGENIC FACTORS. RESEARCHERS WILL INVESTIGATE THE ROLE OF A LIPID-SENSING NUCLEAR RECEPTOR RETINOIC ACID-RELATED ORPHAN RECEPTOR ALPHA (RORA) IN REGULATING CHRONIC SUBRETINAL INFLAMMATION TO ELUCIDATE AMD PATHOGENESIS. THEY WILL ASSESS IF GENETIC DELETION OF RORA IN A TYPE OF INFLAMMATORY CELLS MAY LEAD TO LIPID DYSREGULATION AND CHRONIC INFLAMMATION. NAME OF ORGANIZATION OR GOVERNMENT: JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY KRISHNA SINGH, PHD, ENTITLED: (M2024003F) NRF2 PROTEIN ENHANCES NATURAL ANTIOXIDANT DEFENSES BY CELLULAR ACETYLATION. INVESTIGATOR'S SUMMARY: IN AGE-RELATED MACULAR DEGENERATION (AMD), RETINAL PIGMENT EPITHELIAL (RPE) CELLS ARE DAMAGED BY OXIDATIVE STRESS. NRF2 IS A PROTEIN THAT PROTECTS AGAINST OXIDATIVE STRESS; HOWEVER, NRF2 SIGNALING DECLINES IN AMD. DR. SINGH AND HIS TEAM PROPOSE TO FIND A CAUSE FOR NRF2 SIGNALING DECLINE, CALLED ACETYLATION, A PROCESS THAT MODIFIES PROTEINS TO CHANGE HOW GENES ARE PRODUCED. RESEARCHERS WILL TREAT RPE CELLS WITH SMOKE AND VERIFY IF THE ACETYLATING NRF2 WILL PREVENT ITS DECLINE. IF SUCCESSFUL, THEY WILL HAVE A FAVORABLE STRATEGY FOR TREATING AMD. NAME OF ORGANIZATION OR GOVERNMENT: SCHEPENS EYE RESEARCH INSTITUTE, INC. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY SHINTARO SHIRAHAMA, MD, PHD, ENTITLED: (M2024004F) DEVELOPMENT OF A TRANSPLANT-INDEPENDENT THERAPY FOR RPE DYSFUNCTION. INVESTIGATOR'S SUMMARY: AGING IS A CRITICAL RISK FACTOR FOR DEVELOPING AGE-RELATED MACULAR DEGENERATION (AMD), WHICH IMPLIES THAT YOUNG RETINAL PIGMENT EPITHELIUM (RPE) CELLS CAN SUCCESSFULLY COMBAT THE UNDERLYING CAUSES OF AMD. CONVERSELY, AS RPE CELLS AGE, THEY UNDERGO ALTERATIONS, RENDERING THEM MORE SUSCEPTIBLE TO AMD PATHOGENESIS. DR. SHIRAHAMA'S TEAM FOUND THAT EPIGENETIC REPROGRAMMING THROUGH OSK (OCT4, SOX2, AND KLF4) TRANSDUCTION COULD REVERSE THE CELLULAR BIOLOGICAL AGE AND RESTORE FUNCTION. THEREFORE, IF THEY CAN REVERSE THE BIOLOGICAL AGE OF RPE CELLS, THESE YOUNGER CELLS COULD SUCCESSFULLY COMBAT THE DISEASE, STOPPING FURTHER PROGRESSION AND RESTORING FUNCTIONAL VISION. |
| PART II, LINE 1(H) CONTINUED | NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WASHINGTON (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY JULIETTE WOHLSCHLEGEL, PHD, ENTITLED: (M2024005F) REGENERATING THE HUMAN RETINA. INVESTIGATOR'S SUMMARY: THE HUMAN RETINA CANNOT REGENERATE AFTER DISEASES LIKE AGE-RELATED MACULAR DEGENERATION, WHICH OFTEN LEADS TO BLINDNESS. HOWEVER, A FEW SPECIES INCLUDING FISH CAN REGENERATE NEW RETINAL CELLS THAT EVENTUALLY RESTORE VISUAL FUNCTION. THE REGENERATIVE PROCESS IS DRIVEN BY THE MLLER GLIA, A SUPPORT CELL IN THE RETINA. RESEARCHERS ARE NOW PARTIALLY ABLE TO RECAPITULATE THIS PHENOMENON IN THE HUMAN RETINA. USING THIS NEW STRATEGY, THEY PLAN TO TEST THE REGENERATIVE CAPACITY OF A SPECIFIC ZONE OF THE HUMAN RETINA: THE MACULA. DR. WOHLSCHLEGEL AND HER TEAM NEXT PROPOSE TO TEST DIFFERENT FACTORS TO SPECIFICALLY STIMULATE CONE PHOTORECEPTOR REGENERATION FROM MLLER GLIA. NAME OF ORGANIZATION OR GOVERNMENT: THE PENNSYLVANIA STATE UNIVERSITY COLLEGE OF MEDICINE (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY SANDEEP MOOTHEDATH SUBRAHMANIAN, PHD, ENTITLED: (M2024006F) UNDERSTANDING EARLY EVENTS IN AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) IS A LEADING CAUSE OF VISION LOSS AMONG THE ELDERLY POPULATION. A SIGNIFICANT CHALLENGE IN ADDRESSING AMD IS THE LACK OF UNDERSTANDING OF THE EARLY MOLECULAR EVENTS THAT CONTRIBUTE TO ITS DEVELOPMENT. THIS PROJECT AIMS TO EXPLORE A NOVEL MOLECULAR SWITCH THAT PLAYS A ROLE IN THE FAILED ANTIOXIDANT AND INFLAMMATORY RESPONSES IN RETINAL PIGMENT EPITHELIUM WITH AGING. THE FINDINGS ARE EXPECTED TO IDENTIFY NEW TARGETS FOR THERAPEUTICS THAT ARE PREVENTATIVE OR PROVIDE INTERVENTIONS EARLY IN THE DEVELOPMENT OF AMD. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF COLORADO (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY MIGUEL FLORES-BELIVER, PHD, ENTITLED: (M2024008N) EXOSOMES & AUTOPHAGY: SUSPICIOUS PARTNERS IN DRUSEN BIOGENESIS AND AMD. INVESTIGATOR'S SUMMARY: THE RESEARCH TEAM SEEKS TO UNDERSTAND HOW LITTLE VESICLES, CALLED EXOSOMES, THAT RETINAL PIGMENT EPITHELIUM (RPE) AND RETINAL CELLS SECRETE AND CONTAIN MANY CELLULAR BIOPRODUCTS CONTRIBUTE TO DRUSEN FORMATION AND THE PROGRESSION OF AMD. THEY WILL ALSO IDENTIFY BIOACTIVE MOLECULES RELEASED IN EXOSOMES THAT COULD SERVE AS POTENTIAL BIOMARKERS FOR AMD. THE GOAL IS TO BRIDGE BASIC RESEARCH ON AMD WITH CLINICAL APPLICATION BY TRANSFORMING OUR UNDERSTANDING OF AMD PATHOPHYSIOLOGY AND DRUSEN FORMATION. THIS INVOLVES PRECLINICAL VALIDATION, INVESTIGATING INTERVENTIONS TARGETING AUTOPHAGY AND EXOSOMES, BIOMARKER DEVELOPMENT, DIAGNOSTIC TOOL INTEGRATION, THERAPEUTIC DEVELOPMENT, AND PATIENT STRATIFICATION FOR PERSONALIZED TREATMENTS. THROUGH THESE STRATEGIES, WE AIM TO IMPROVE AMD DIAGNOSIS, TREATMENT, AND PATIENT OUTCOMES. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY HEIKE KROEGER, PHD, ENTITLED: (M2024010N) DECODING VISION: CONE DEVELOPMENT IN RETINAL ORGANOIDS AND ANOLE LIZARD. INVESTIGATOR'S SUMMARY: THE LOSS OF CONE PHOTORECEPTOR CELLS DURING AGE-RELATED MACULAR DEGENERATION (AMD) CAN LEAD TO IRREVERSIBLE VISION LOSS. REPAIRING THESE SPECIALIZED CELLS COULD CHANGE THE OVERALL APPROACH OF AMD THERAPIES AND COMPLEMENT CURRENT TREATMENT OPTIONS. THIS RESEARCH INVESTIGATES HOW CONE PHOTORECEPTOR OUTER SEGMENTS ARE FORMED AND REGENERATED USING STEM CELL ORGANOIDS AND THE BROWN ANOLE LIZARD, A NOVEL RESEARCH MODEL FOR CONE PHOTORECEPTOR DISEASES. FINDINGS WILL IDENTIFY A NEW STRATEGY AND POTENTIAL NEW THERAPEUTIC TARGETS TO IMPROVE AND PREVENT LOSS OF CONE PHOTORECEPTOR CELL FUNCTION DURING AMD. NAME OF ORGANIZATION OR GOVERNMENT: GEROGIA TECH RESEARCH CORPORATION (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY HANNAH YOUNGBLOOD, PHD, ENTITLED: (G2024001F) EFFECTS OF PSEUDOEXFOLIATION GLAUCOMA VARIANTS IN LOXL1. INVESTIGATOR'S SUMMARY: GENETIC VARIANTS IN LOXL1 CAN ALTER RISK FOR PSEUDOEXFOLIATION GLAUCOMA (XFG), A BLINDING DISEASE THAT AFFECTS MORE THAN 10 MILLION PEOPLE. THIS PROJECT SEEKS TO DETERMINE HOW THESE VARIANTS ALTER THE STRUCTURE AND FUNCTION OF THE LOXL1 PROTEIN. SUCCESSFUL COMPLETION OF THIS PROJECT WILL PROVIDE A BETTER UNDERSTANDING OF HOW LOXL1 VARIANTS CONTRIBUTE TO XFG AND PROVIDE GROUNDWORK FOR THERAPEUTIC DEVELOPMENT. THIS PROJECT WOULD BE THE FIRST TO CHARACTERIZE THE PROTEIN STRUCTURE OF LOXL1 WITH AND WITHOUT PSEUDOEXFOLIATION GLAUCOMA-ASSOCIATED VARIANTS. RESULTS WILL OFFER NOVEL INSIGHT INTO HOW PSEUDOEXFOLIATION GLAUCOMA-ASSOCIATED VARIANTS CONTRIBUTE TO THE DISEASE BY ALTERING INTERACTIONS WITH FIBULIN-5, A PROTEIN NECESSARY FOR PROPER LOXL1 LOCALIZATION. NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY SHRUTI PATIL, PHD, ENTITLED: (G2024002F) RGC AXON DEGENERATION IN A 3D MICROFLUIDIC HYDROGEL MODEL. INVESTIGATOR'S SUMMARY: RETINAL GANGLION CELL (RGC) AXONS TRAVERSING THE OPTIC NERVE HEAD ARE HIGHLY SUSCEPTIBLE TO GLAUCOMATOUS DAMAGE, YET THE LINK BETWEEN OPTIC NERVE HEAD BIOMECHANICS AND RGC AXONAL DEGENERATION REMAINS POORLY UNDERSTOOD. TO ADDRESS THIS, RESEARCHERS WILL IMPLEMENT 3D PLATFORMS INTEGRATING MICROFLUIDICS AND HYDROGELS WITH TUNABLE STIFFNESS TO MODEL BIOMECHANICAL ASPECTS AFFECTING RGC AXONS IN THE OPTIC NERVE HEAD. UPON COMPLETION, THE STUDY WILL UNCOVER INSIGHTS INTO RGC AXONAL DYSFUNCTION DUE TO BIOMECHANICAL CHANGES IN CONTEXT OF HUMAN TISSUE USING A STEM CELL MODEL. BY TARGETING THE BIOMECHANICAL ASPECTS OF THE LAMINA CRIBROSA, THE STUDY COULD LEAD TO NOVEL THERAPEUTIC INTERVENTIONS BEYOND TRADITIONAL APPROACHES REGULATING INTRAOCULAR PRESSURE. INCORPORATING HYDROGELS IN THE MICROFLUIDIC SYSTEM ALLOWS STUDY OF COMPLEX CELLULAR INTERACTIONS IN A 3D MICROENVIRONMENT, APPLICABLE TO OTHER AGE-ASSOCIATED OPTIC NERVE DEGENERATION. THIS OFFERS HOPE FOR MORE EFFECTIVE GLAUCOMA TREATMENTS. NAME OF ORGANIZATION OR GOVERNMENT: GEROGIA TECH RESEARCH CORPORATION (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY HAIYAN LI, PHD, ENTITLED: (G2024003F) THE ROLE OF MICROTUBULES IN GLAUCOMATOUS SCHLEMM'S CANAL MECHANOBIOLOGY. INVESTIGATOR'S SUMMARY: INTRAOCULAR PRESSURE IS LARGELY CONTROLLED BY TISSUES AT OR NEAR SCHLEMM'S CANAL INNER WALL ENDOTHELIUM, WHERE REDUCED FLUID CONDUCTIVITY OCCURS IN GLAUCOMA. THIS PROJECT AIMS TO INVESTIGATE THE IMPACT OF MICROTUBULES, CRUCIAL COMPONENTS OF THE CYTOSKELETON, ON SCHLEMM'S CANAL CELL MECHANOBIOLOGY AND INTRAOCULAR PRESSURE, A KEY RISK FACTOR FOR GLAUCOMA. THIS WORK WILL IMPROVE OUR UNDERSTANDING OF SCHLEMM'S CANAL CELL MECHANOBIOLOGY, CREATING A FOUNDATION FOR FUTURE STUDIES INVESTIGATING HOW MICROTUBULES IN SCHLEMM'S CANAL CELLS INFLUENCE OUTFLOW FACILITY AND OCULAR HYPERTENSION. ADDITIONALLY, IT WILL OPEN AVENUES FOR BOTH EX VIVO AND IN VIVO INVESTIGATIONS OF CANDIDATE DRUGS TARGETING THE HYDRAULIC CONDUCTIVITY OF SCHLEMM'S CANAL INNER WALL CELLS AS TREATMENTS FOR OCULAR HYPERTENSION IN PRIMARY OPEN-ANGLE GLAUCOMA. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF PITTSBURGH (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY BINGRUI WANG, PHD, ENTITLED: (G2024004F) HOW PRESSURE DEFORMS THE EYE AND LEADS TO GLAUCOMA VISION LOSS. INVESTIGATOR'S SUMMARY: BLINDNESS IN GLAUCOMA IS CAUSED BY DAMAGE TO AXONS THAT CARRY VISUAL INFORMATION TO THE BRAIN. DAMAGE OFTEN STARTS IN THE BACK OF THE EYE AND IS DUE TO HIGH EYE PRESSURE WHICH MECHANICALLY DEFORMS AXONS. HOWEVER, THE LINK BETWEEN AXON DEFORMATION AND LONG-TERM DAMAGE IS UNCLEAR. USING ANIMAL MODELS, RESEARCHERS WILL INVESTIGATE AXON DEFORMATION AND ITS LINK TO DAMAGE TO UNDERSTAND GLAUCOMA'S CAUSES. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY MENGYA ZHAO, PHD, ENTITLED: (G2024005F) WHY CERTAIN RETINA GANGLION CELLS STAY STRONG IN GLAUCOMA. INVESTIGATOR'S SUMMARY: THIS PROJECT FOCUSES ON UNDERSTANDING THE MECHANISMS UNDERLYING NEURONAL LOSS IN GLAUCOMA, WHICH CAN LEAD TO IRREVERSIBLE BLINDNESS. THIS DISEASE VARIABLY IMPACTS MANY EYE NEURONS. USING A COMBINATION OF CUTTING-EDGE TECHNIQUES, RESEARCHERS WILL INVESTIGATE WHY CERTAIN NEURONS ARE MORE RESILIENT THAN OTHERS. THIS WORK COULD UNLOCK NEW TREATMENTS, OFFERING A BREAKTHROUGH IN GLAUCOMA THERAPY AND EYE CARE. |
| PART II, LINE 1(H) CONTINUED | NAME OF ORGANIZATION OR GOVERNMENT: SUNY UPSTATE MEDICAL UNIVERSITY (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY SAMUEL HERBERG, PHD, ENTITLED: (G2024006S) INVESTIGATE HOW THE MICROENVIRONMENT AFFECTS SCHLEMM'S CANAL CELL BEHAVIOR. INVESTIGATOR'S SUMMARY: HIGH-PRESSURE GLAUCOMA IS A LEADING CAUSE OF BLINDNESS WORLDWIDE, BUT THE CAUSAL MECHANISMS ARE UNCLEAR. USING OUR UNIQUE 3D FLUID DRAINAGE TISSUE MODEL SYSTEM, WE SEEK TO INVESTIGATE THE CONTRIBUTIONS OF GLAUCOMATOUS BIOMECHANICAL CUES IN DRIVING SCHLEMM'S CANAL CELL MECHANO-DYSFUNCTION. THIS WORK WILL SET THE STAGE FOR IDENTIFICATION OF FUTURE GLAUCOMA THERAPIES TARGETING CELLULAR BIOMECHANICS. NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF VIRGINIA (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY XIARONG LIU, PHD, ENTITLED: (G2024008S) LIGHT-MEDIATED SLEEP AND MOOD DISORDERS IN GLAUCOMA. INVESTIGATOR'S SUMMARY: A SMALL POPULATION OF RETINAL GANGLION CELLS, THE IPRGCS, COMMUNICATES LIGHT INFORMATION FROM THE EYES TO THE BRAIN FOR PURPOSES OTHER THAN VISION SUCH AS THE REGULATION OF SLEEP AND MOOD. BECAUSE GLAUCOMA PATIENTS OFTEN SUFFER FROM LIGHT-MEDIATED SLEEP AND MOOD DISORDERS, WE AIM TO UNDERSTAND HOW IPRGCS CONTROL LIGHT'S EFFECTS ON MOOD AND SLEEP. THIS STUDY REPRESENTS A FIRST ATTEMPT TO EXPLORE THE CHANGES DUE TO GLAUCOMA IN THE IPRGC-BASED NEURAL CIRCUITRY RESPONSIBLE FOR NON-VISUAL RESPONSES TO LIGHT. THIS RESEARCH WILL CONTRIBUTE TO OUR UNDERSTANDING OF THE NEURAL PATHWAYS UNDERLYING MOOD AND BEHAVIORAL CHANGES EXPERIENCED BY GLAUCOMA PATIENTS. SUCH INSIGHTS ARE CRUCIAL FOR ENHANCING PATIENT CARE AND DEVELOPING BETTER TREATMENTS AS GLAUCOMA ADVANCES AND EVOLVES. NAME OF ORGANIZATION OR GOVERNMENT: OREGON HEALTH & SCIENCE UNIVERSITY (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY DIANA LOZANO, PHD, ENTITLED: (G2024009S) IOP-RELATED GENE RESPONSES IN GLAUCOMA TISSUES. INVESTIGATOR'S SUMMARY: ELEVATED INTRAOCULAR PRESSURE (IOP) IS A LEADING RISK FACTOR FOR PRIMARY OPEN-ANGLE GLAUCOMA. YET, THE CELLULAR EVENTS THAT COMPRISE PROTECTIVE HOMEOSTATIC IOP RESPONSES, OR DELETERIOUS EVENTS LEADING TO TISSUE INJURY, ARE CURRENTLY POORLY UNDERSTOOD. WE WILL INVESTIGATE HOW MILD AND REPEAT IOP ELEVATIONS MODIFY THE MOLECULAR MECHANISMS IN OCULAR TISSUES IMPLICATED IN GLAUCOMA PATHOGENESIS. NAME OF ORGANIZATION OR GOVERNMENT: GEORGIA INSTITUTE OF TECHNOLOGY (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY C. ROSS ETHIER, PHD, ENTITLED: (CG2020001) NEXT-GENERATION GLAUCOMA DRUGS TO SELECTIVELY RELEASE THE PRESSURE-BUILDING BLOCK IN SCHLEMM'S CANAL. INVESTIGATOR'S SUMMARY: WE NOW UNDERSTAND THAT ENDOTHELIAL CELLS OF THE INNER WALL OF SCHLEMM'S CANAL (SC) PLAY A KEY ROLE IN HOMEOSTATIC CONTROL MECHANISMS THAT MAINTAIN IOP WITHIN A TARGET RANGE. THE LONG-TERM GOAL OF THIS PROJECT IS TO DEVELOP NOVEL THERAPIES THAT DIRECTLY TARGET SC CELLS TO IMPROVE IOP CONTROL. THESE TARGETED THERAPIES WILL BE HIGHLY EFFECTIVE DUE TO THEIR SPECIFICITY AND WILL THUS GREATLY BENEFIT GLAUCOMA PATIENTS. NAME OF ORGANIZATION OR GOVERNMENT: DUKE UNIVERSITY (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY W. DANIEL STAMER, PHD, ENTITLED: (CG2020002) NEXT-GENERATION GLAUCOMA DRUG DEVELOPMENT. INVESTIGATOR'S SUMMARY: FOR THE PROJECT, WE WILL SCREEN CANDIDATE ADENO-ASSOCIATED VIRUSES AND ENGINEERED PROMOTERS CLONED INTO LENTIVIRUSES OBTAINED FROM COLLABORATORS IN HUMAN SCHLEMM'S CANAL CELLS IN VITRO AND ANTERIOR SEGMENTS EX VIVO FOR SELECTIVE TROPISM TO/ACTIVITY IN TRABECULAR MESHWORK VERSUS SCHLEMM'S CANAL. NAME OF ORGANIZATION OR GOVERNMENT: COLUMBIA UNIVERSITY (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY SIMON JOHN, PHD, ENTITLED: (CG2020004) NOVEL GENE-THERAPY APPROACH FOR GLAUCOMA. INVESTIGATOR'S SUMMARY: THE PROJECT AIMS TO DEVELOP AND TEST RESOURCES FOR SCHLEMM'S CANAL SPECIFIC TARGETING AND EXPRESSION OF GENES FOR GENE THERAPY. SUCCESSFUL DEVELOPMENT OF THIS TARGETED THERAPY WILL HELP CONTROL EYE PRESSURE MORE EFFECTIVELY AND PROVIDE BETTER TREATMENT OPTIONS FOR GLAUCOMA PATIENTS. NAME OF ORGANIZATION OR GOVERNMENT: STANFORD UNIVERSITY (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY JEFFREY GOLDBERG, PHD, ENTITLED: (CG2022001) NEUROPROTECTION AND NEUROENHANCEMENT IN GLAUCOMA. INVESTIGATOR'S SUMMARY: THE GOAL OF THIS PROJECT IS TO EVALUATE SAFETY AND PROOF OF CONCEPT FOR WHETHER CILIARY NEUROTROPHIC FACTOR (CNTF) CAN ENHANCE VISION OR PROTECT AGAINST VISION LOSS IN GLAUCOMA. |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Form990 Of Other Organizations | Yes (X) | Form990OfOtherOrganizationsInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | 0 | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (11 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STACY PAGOS HALLER | ||||||||||||||
| PRESIDENT/CEO | $408,714 | $0 | $0 | $0 | $1,693 | $0 | $29,700 | $0 | $27,785 | $0 | $467,892 | $0 | $0 | $0 |
| NANCY LYNN | ||||||||||||||
| SR. VP STRATEGIC PARTNERSHIPS | $259,564 | $0 | $0 | $0 | $1,584 | $0 | $24,465 | $0 | $37,027 | $0 | $322,640 | $0 | $0 | $0 |
| R BRIAN ELDERTON | ||||||||||||||
| SR. VP, DEVELOPMENT | $252,137 | $0 | $0 | $0 | $1,715 | $0 | $23,361 | $0 | $24,967 | $0 | $302,180 | $0 | $0 | $0 |
| DIANE BOVENKAMP PHD | ||||||||||||||
| VP, SCIENTIFIC AFFAIRS | $189,665 | $0 | $0 | $0 | $552 | $0 | $17,075 | $0 | $5,165 | $0 | $212,457 | $0 | $0 | $0 |
| DAVID F MARKS CPA CMA | ||||||||||||||
| VP, FINANCE & ADMIN TILL 10/2023 | $155,687 | $0 | $0 | $0 | $1,254 | $0 | $15,151 | $0 | $39,533 | $0 | $211,625 | $0 | $0 | $0 |
| KACI BAEZ | ||||||||||||||
| VP, INTEGRATED MKTING & COMM. | $172,402 | $0 | $0 | $0 | $200 | $0 | $4,650 | $0 | $21,999 | $0 | $199,251 | $0 | $0 | $0 |
| SHARYN ROSSI PHD DIR OF | ||||||||||||||
| SCIENT. PROGRAMS, NEUROSCIENCE | $125,121 | $0 | $0 | $0 | $240 | $0 | $8,775 | $0 | $35,057 | $0 | $169,193 | $0 | $0 | $0 |
| LISA MORGAN | ||||||||||||||
| DIRECTOR OF ANNUAL GIVING | $127,764 | $0 | $0 | $0 | $552 | $0 | $12,139 | $0 | $21,508 | $0 | $161,963 | $0 | $0 | $0 |
| AYO ABRAHAM CPA CGMA | ||||||||||||||
| CONTROLLER UNTIL 8/2023 | $138,238 | $0 | $0 | $0 | $688 | $0 | $9,371 | $0 | $11,985 | $0 | $160,282 | $0 | $0 | $0 |
| JEFFREY HONAKER | ||||||||||||||
| SR. MGR. OPS AND BUILDING | $111,125 | $0 | $0 | $0 | $1,032 | $0 | $10,271 | $0 | $34,133 | $0 | $156,561 | $0 | $0 | $0 |
| PREETI SUBRAMANIAN PHD DIR | ||||||||||||||
| OF SCIENT. PROGRAMS, VISION SCIENCE | $134,875 | $0 | $0 | $0 | $240 | $0 | $12,139 | $0 | $3,518 | $0 | $150,772 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 3 | FormAndLineReferenceDesc |
| Explanation | THE LAST COMPENSATION SURVEY WAS COMPLETED ON 3/9/2022. | ExplanationTxt |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 20 | ContributionCnt |
| Noncash Contributions Rpt F990 | $87,848 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | FMV | MethodOfDeterminingRevenuesTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | Yes (1) | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | 0 | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, COLUMN (B): | FormAndLineReferenceDesc |
| Explanation | BRIGHTFOCUS REPORTS THE NUMBER OF CONTRIBUTIONS IN PART I, COLUMN B. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (9 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION: | BRIGHTFOCUS FOUNDATION FUNDS EXCEPTIONAL RESEARCH WORLDWIDE TO DEFEAT ALZHEIMER'S DISEASE, MACULAR DEGENERATION, AND GLAUCOMA AND PROVIDES EXPERT INFORMATION ON THESE HEARTBREAKING DISEASES. OUR VISION IS: A WORLD FREE FROM DISEASES OF MIND AND SIGHT. COLLECTIVELY, MORE THAN 300 MILLION PEOPLE WORLDWIDE SUFFER FROM THESE DISEASES. BRIGHTFOCUS HAS A PROVEN TRACK RECORD OF SUPPORTING THE MOST INNOVATIVE, EARLY-STAGE RESEARCH SEEKING TO FOSTER A BETTER UNDERSTANDING OF, TREATMENTS FOR, AND ULTIMATELY, A CURE FOR, THESE AGE-RELATED DISEASES WITH NO CURE. SINCE 1973, BRIGHTFOCUS HAS AWARDED MORE THAN $297 MILLION IN RESEARCH GRANTS TO THOUSANDS OF SCIENTISTS IN 25 COUNTRIES THROUGH ITS THREE PROGRAMS: ALZHEIMER'S DISEASE RESEARCH, MACULAR DEGENERATION RESEARCH, AND NATIONAL GLAUCOMA RESEARCH. THE RESEARCH WE SUPPORT IS CAREFULLY CHOSEN BY OUR SCIENTIFIC REVIEW COMMITTEES, COMPRISING WORLD-RENOWNED RESEARCHERS AND LEADERS IN THEIR FIELDS. OUR RESEARCH FUNDING HAS LED TO MAJOR CONTRIBUTIONS TO UNDERSTANDING THESE DISEASES AND SUPPORT FOR SCIENTISTS WHO HAVE RECEIVED PRESTIGIOUS AWARDS, INCLUDING TWO NOBEL PRIZES. AN INDICATOR OF OUR ABILITY TO PUSH NEW BOUNDARIES OF KNOWLEDGE IS THAT BRIGHTFOCUS-SUPPORTED RESEARCH WAS FOUND TO HAVE HAD 10 TIMES THE IMPACT ON DRIVING FUTURE SCIENCE THAN WORK SUPPORTED BY MANY OTHER ORGANIZATIONS. THE WORLD-CLASS RESEARCH IDENTIFIED AND SUPPORTED BY BRIGHTFOCUS IS ON THE CUTTING EDGE OF THE FIGHT TO SAVE MIND AND SIGHT. OUR FUNDING ACTS AS A CATALYST IN EARLY-STAGE RESEARCH, AND BRIGHTFOCUS RESEARCH PROGRAMS ARE DESIGNED TO PROVIDE INITIAL FUNDING FOR HIGHLY INNOVATIVE EXPERIMENTAL IDEAS. DUE TO THE STRUCTURED GRANT REVIEW AND APPROVAL PROCESS, THE RESEARCH IMPACT OF BRIGHTFOCUS IS VERY HIGH. MOST RECIPIENTS OF BRIGHTFOCUS FUNDING GO ON TO RECEIVE FUTURE GRANTS FROM OTHER SOURCES THAT ARE UP TO 10 TIMES LARGER THAN THE ORIGINAL BRIGHTFOCUS AWARD. THIS HIGH RETURN ON BRIGHTFOCUS INVESTMENT SPEAKS TO OUR ABILITY TO IDENTIFY PROMISING RESEARCH IN ITS EARLIEST STAGES AND SPAWN FUTURE SCIENTIFIC DISCOVERIES. IT IS OUR FIRM BELIEF THAT HAVING THE COURAGE TO INVEST IN INNOVATIVE IDEAS WILL LEAD TO REVOLUTIONARY APPROACHES AND LIFE-SAVING BREAKTHROUGHS. ALONG WITH FUNDING CUTTING-EDGE RESEARCH TO FIND CURES FOR SOME OF THE WORLD'S COSTLIEST DISEASES, BRIGHTFOCUS ALSO PROVIDES FREE, EXPERT-VETTED EDUCATIONAL MATERIALS AND SUPPORT TO HUNDREDS OF THOUSANDS OF PEOPLE IMPACTED BY THESE DISEASES NATIONWIDE. WE GROUND THESE EDUCATIONAL MATERIALS IN THE LATEST RESEARCH FINDINGS AND BREAKTHROUGHS. BRIGHTFOCUS ALSO INCREASES PUBLIC AWARENESS OF ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA, AND COMMUNICATES WITH THOUGHT LEADERS AND ELECTED OFFICIALS ABOUT THE IMPORTANCE OF SCIENTIFIC RESEARCH IN THESE AREAS. BRIGHTFOCUS' AWARD-WINNING PUBLIC SERVICE ANNOUNCEMENTS (PSAS) HAVE APPEARED ON TELEVISION, RADIO, AND IN PRINT THROUGHOUT THE NATION. THE IMPACT OF ALZHEIMER'S, MAKE A PLAN TODAY: GET YOUR EYES CHECKED, AND FINDING ANSWERS IN THE FIGHT AGAINST ALZHEIMER'S SEEK TO RAISE AWARENESS ABOUT THESE DISEASES AND THE IMPORTANCE OF EARLY DETECTION. SIMILAR MESSAGES HAVE BEEN DELIVERED THROUGH DONATED PRINT PSA SPACE IN AIRPORTS AND TRAIN STATIONS, AS WELL AS AT PHARMACIES, SUPERMARKETS AND DIGITALLY. IN FISCAL YEAR 2024, THESE PSA MESSAGES GENERATED $24,713,985 IN DONATED MEDIA SERVICES AND GARNERED OVER 405 MILLION IMPRESSIONS. WE CONTINUE TO INCREASE OUR PRINT PUBLICATIONS, MANY IN SPANISH, THAT PROVIDE HELPFUL INFORMATION TO PATIENTS AND CAREGIVERS, AND REGULARLY PRODUCE NEW VIDEO AND AUDIO RESOURCES IN CONJUNCTION WITH ALLIES IN THE MEDICAL AND SCIENTIFIC COMMUNITIES. PARTNERING WITH SEVERAL HIGH-PROFILE PUBLIC AND PRIVATE ORGANIZATIONS, BRIGHTFOCUS IS HELPING TO BETTER EDUCATE THE PUBLIC ON THE LATEST RESEARCH DEVELOPMENTS PERTAINING TO ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA, AS WELL AS THE IMPORTANCE OF EQUITABLE PARTICIPATION IN CLINICAL RESEARCH TO ACCELERATE THE PATH TO CURES FOR NEURODEGENERATIVE DISEASES. SPECIFICALLY, BRIGHTFOCUS PRODUCES AND DISSEMINATES FREE PROGRAMS INCLUDING: BRIGHTFOCUS VISION CHATS. SINCE 2014, THESE AUDIO DISCUSSIONS HAVE BROUGHT TOGETHER PATIENTS AND CAREGIVERS FOR INTERACTIVE MONTHLY TELEPHONE FORUMS TO LEARN FROM AND ASK QUESTIONS OF LEADING VISION DISEASE EXPERTS. THE CHATS ARE ARCHIVED ON OUR WEBSITE, WITH AUDIO AND PRINT TRANSCRIPTS AVAILABLE IN SEVERAL ACCESSIBLE FORMATS ONLINE, INCLUDING AS PODCASTS ON SPOTIFY AND APPLE ITUNES. ZOOM IN ON DEMENTIA AND ALZHEIMER'S, A MONTHLY VIRTUAL DISCUSSION OPEN TO THE PUBLIC FEATURING WORLD-RENOWNED RESEARCH SCIENTISTS WHO SHARE THE LATEST BREAKTHROUGHS AND FINDINGS IN THE FIELD. ALL EPISODES ARE RECORDED AND AVAILABLE TO WATCH ON DEMAND ON OUR WEBSITE AND YOUTUBE. WE REGULARLY PUBLISH ARTICLES AND RESOURCES PROVIDING LAY-PERSON INFORMATION ABOUT COMMONLY ASKED DISEASE QUESTIONS. OVER THREE MILLION VISITORS EACH YEAR TO OUR WEBSITE, WWW.BRIGHTFOCUS.ORG, FIND A WEALTH OF INFORMATION ON RESEARCH, SYMPTOMS, TREATMENTS, AND CAREGIVER SUPPORT. BRIGHTFOCUS IS A PRESENTING PARTNER OF SEVERAL DOCUMENTARY FILMS, INCLUDING REMEMBERING GENE WILDER AND GLEN CAMPBELL: I'LL BE ME, AND EXECUTES ASSOCIATED EDUCATIONAL IMPACT CAMPAIGNS. THESE FILMS ARE SHOWN IN COMMUNITY SETTINGS ACROSS THE COUNTRY TO INCREASE AWARENESS OF, AND PARTICIPATION IN, ALZHEIMER'S CLINICAL RESEARCH. BRIGHTFOCUS HAS A LONG-RUNNING AND ROBUST DIRECT MAIL PROGRAM ACROSS THE THREE RESEARCH AREAS IT SUPPORTS. BRIGHTFOCUS SHARES MAILS AWARENESS-RAISING MATERIALS ACROSS ITS THREE PROGRAM AREAS TO OVER 520,000 NATIONAL HOUSEHOLDS, WITH MESSAGES FOCUSING ON: RISK FACTORS AND SYMPTOM RECOGNITION THROUGH PUBLIC AWARENESS AND STEPS THE PUBLIC SHOULD TAKE THAT MAY HELP REDUCE THEIR RISK. LIFESTYLE CHOICES THAT PROMOTE GOOD HEALTH, ENCOURAGING READERS TO TAKE ACTION TO REDUCE THE LIKELIHOOD OF THE ONSET OF THE DISEASE. RESEARCH RESULTS AND TREATMENTS AVAILABLE TO ADDRESS THE DISEASE. BRIGHTFOCUS REGULARLY INTERACTS WITH ADVOCACY ORGANIZATIONS, GOVERNMENTS AT ALL LEVELS, AND MEMBERS OF THE MEDIA, TO CALL GREATER ATTENTION TO DISEASES OF MIND AND SIGHT AND SHARE THE LATEST RESEARCH AND BEST PRACTICES WITH PUBLIC FIGURES AND KEY STAKEHOLDERS. THROUGH OUR OWN OUTREACH EFFORTS, AS WELL AS VIA ACTIVE ROLES IN ADVOCACY COALITIONS, WE HELP ADVANCE THE CAUSE OF PIONEERING SCIENCE AND BETTER POSITION BRIGHTFOCUS AS A RESOURCE FOR THOSE STRUGGLING WITH AND SEARCHING FOR CURES FOR THESE TERRIBLE DISEASES. BRIGHTFOCUS IS THE PRESENTING SPONSOR OF THE HELEN KELLER PRIZE FOR VISION RESEARCH, ONE OF THE MOST PRESTIGIOUS RECOGNITIONS IN THE FIELD. SELECTED BY A PANEL OF THE WORLD'S FOREMOST VISION SCIENTISTS, EACH YEAR'S LAUREATE IS HONORED FOR A GROUNDBREAKING CONTRIBUTION OR DISCOVERY TO SAVE SIGHT. BRIGHTFOCUS BEGAN ITS SPONSORSHIP IN 2015 TO CALL GREATER ATTENTION TO VISION RESEARCH ACROSS THE PRIVATE AND PUBLIC SECTORS. BRIGHTFOCUS WAS HONORED IN 2023 FOR ITS CONTRIBUTIONS TO ADVANCING GLOBAL VISION RESEARCH BY THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY (ARVO) FOUNDATION. |
| FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: | ALZHEIMER'S DISEASE RESEARCH (ADR) ALZHEIMER'S DISEASE IS THE ONLY CAUSE OF DEATH AMONG THE TOP 10 IN AMERICA WITHOUT A WAY TO PREVENT, CURE, OR EVEN SLOW ITS PROGRESSION. IT IS AN IRREVERSIBLE DEGENERATION OF THE BRAIN THAT CAUSES DISRUPTIONS IN MEMORY, COGNITION, PERSONALITY, AND OTHER FUNCTIONS AND INEVITABLY LEADS TO DEATH. AN ESTIMATED 55 MILLION PEOPLE WORLDWIDE HAVE ALZHEIMER'S DISEASE OR OTHER DEMENTIAS, WITH WOMEN AND BLACK AND HISPANIC ADULTS MOST AT RISK. ALZHEIMER'S DISEASE RESEARCH (ADR), A BRIGHTFOCUS FOUNDATION PROGRAM, FUNDS RESEARCH FOCUSED ON UNDERSTANDING THE CAUSES OF ALZHEIMER'S DISEASE, EARLY DETECTION, TREATMENTS TO HELP SLOW OR STOP ITS PROGRESSION, AND ULTIMATELY TO PREVENT THE DISEASE ALTOGETHER. ADR ANNUALLY AWARDS PEER-REVIEWED GRANTS TO SCIENTISTS FROM INSTITUTIONS WORLDWIDE WHO ARE CONDUCTING BIOMEDICAL AND CLINICAL RESEARCH ON ALZHEIMER'S DISEASE. SINCE INCEPTION, ADR HAS CONTRIBUTED MORE THAN $180 MILLION TO DEFEATING ALZHEIMER'S DISEASE. DURING THE FISCAL YEAR ENDING MARCH 31, 2024, ADR AWARDED $5,689,899 IN PEER-REVIEWED GRANT AWARDS TO 23 NEW RESEARCH PROJECTS . NOTABLE PROJECTS INCLUDE: HYPERTENSION AND LIFESTYLE EFFECTS ON RISK OF ALZHEIMER'S (INCLUDING LIPIDS); DRUG DISCOVERY AND BIOMARKERS; THE ROLE OF INFLAMMATION, MICROGLIA AND VASCULAR HEALTH IN DISEASE RISK; LOOKING AT THE MITOCHONDRIA AND CELL ENERGY DEFICIENCIES; ROLE OF SLEEP DISTURBANCES CAUSING INCREASED RISK OF COGNITIVE ISSUES; DIFFERENCES IN GENETICS AND DISEASE RISK FOR UNDERREPRESENTED POPULATIONS; AND BETTER USE OF MODERN TECHNOLOGIES, INCLUDING BIG DATA/AI AND SYSTEMS GENETICS ANALYSIS FOR INCREASED AND DECREASED RISKS. ADDITIONAL INFORMATION ABOUT SPECIFIC PROJECTS IS INCLUDED IN SCHEDULES F & I. BRIGHTFOCUS IS HONORED TO HAVE SUPPORTED THE EARLY RESEARCH OF TWO NOBEL PRIZE WINNERS: DR. STANLEY PRUSINER AND DR. PAUL GREENGARD, WHOSE WORK HAS BEEN INSTRUMENTAL TO OUR CURRENT UNDERSTANDING OF ALZHEIMER'S DISEASE. BRIGHTFOCUS CONTINUES ITS PARTNERSHIP WITH THE ACADEMIC JOURNAL MOLECULAR NEURODEGENERATION AS THE OFFICIAL JOURNAL OF BRIGHTFOCUS FOUNDATION. THE JOURNAL PUBLISHES TECHNICAL PAPERS RELATED TO NEURODEGENERATION IN THE THREE DISEASE AREAS. TO ACCELERATE SCIENTIFIC PROGRESS, IT IS AN OPEN-ACCESS JOURNAL, AND ALL CONTENT IS FREE OF CHARGE. THIS OPEN ACCESS ENSURES MAXIMAL REACH OF JOURNAL CONTENTS TO SCIENTISTS AND CARE PROVIDERS WORLDWIDE. MOLECULAR NEURODEGENERATION IS CURRENTLY THE HIGHEST IMPACT OPEN ACCESS JOURNAL IN THE NEUROSCIENCES. IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, ALZHEIMER'S DISEASE RESEARCH PROVIDES EXPERT-VETTED RESOURCES ON DETECTING, TREATING, AND LIVING WITH THE DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG. |
| FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICE: | MACULAR DEGENERATION RESEARCH (MDR) AGE-RELATED MACULAR DEGENERATION IS A LEADING CAUSE OF VISION LOSS IN THE UNITED STATES. IT DESTROYS THE MACULA, THE PART OF THE EYE THAT PROVIDES SHARP, CENTRAL VISION NEEDED FOR SEEING OBJECTS CLEARLY. THE MOST COMMON EYE CONDITION IN PEOPLE AGE 60 AND OLDER, IT CAN LEAD TO VISION LOSS IN ONE OR BOTH EYES, MAKING IT DIFFICULT TO RECOGNIZE FACES, DRIVE A CAR, OR READ. AT LEAST 20 MILLION AMERICANS HAVE SOME TYPE OF MACULAR DEGENERATION, INCLUDING BOTH THE EARLY AND LATER STAGES OF THE WET AND DRY TYPES. MACULAR DEGENERATION RESEARCH (MDR), A BRIGHTFOCUS FOUNDATION PROGRAM, HAS AWARDED NEARLY $53 MILLION TO SCIENTISTS STUDYING THE DISEASE. THE LATEST RESEARCH IS FOCUSED ON NOVEL TREATMENTS, UNDERSTANDING THE CAUSES AND DISEASE PROGRESSION, PREDICTION METHODS AND DISEASE MODELING, DRUG THERAPIES, THE ROLE OF METABOLISM AND IMMUNE RESPONSE IN DISEASE RISK, GENES, AND NEW IMAGING, MACHINE LEARNING, AND SCREENING TECHNIQUES. MDR GRANTS ARE AVAILABLE TO MACULAR DEGENERATION RESEARCHERS WORLDWIDE. MDR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM YOUNG SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON SCIENTIFIC MERIT. DURING THE FISCAL YEAR ENDING MARCH 31, 2024, MDR AWARDED $3,839,035 IN PEER-REVIEWED GRANT AWARDS TO 10 NEW RESEARCH PROJECTS, A TOTAL FUNDING AMOUNT OF $2,850,660. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES F & I. IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, MACULAR DEGENERATION RESEARCH PROVIDES EXPERT-VETTED RESOURCES ON DETECTING, TREATING, AND LIVING WITH THIS DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG. |
| FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE: | NATIONAL GLAUCOMA RESEARCH (NGR) GLAUCOMA IS THE SECOND LEADING CAUSE OF BLINDNESS WORLDWIDE, ACCORDING TO A RECENT REPORT FROM THE WORLD HEALTH ORGANIZATION, APPROXIMATELY 80 MILLION PEOPLE AROUND THE WORLD HAVE GLAUCOMA. MORE THAN THREE MILLION AMERICANS, OVER THE AGE OF 40 ARE LIVING WITH GLAUCOMA, WITH AN ESTIMATED 2.7 MILLION HAVE OPEN-ANGLE GLAUCOMA, THE MOST COMMON TYPE. IN THE UNITED STATES, GLAUCOMA IS A LEADING CAUSE OF BLINDNESS AMONG BLACK AND HISPANIC AMERICANS. WITH EARLY DETECTION AND TREATMENT, GLAUCOMA OFTEN CAN BE MANAGED TO PROTECT EYES FROM MORE SERIOUS VISION LOSS. IT IS ESTIMATED THAT ONLY HALF OF THE PEOPLE LIVING WITH GLAUCOMA ARE AWARE THAT THEY HAVE THE DISEASE. NATIONAL GLAUCOMA RESEARCH (NGR), A BRIGHTFOCUS FOUNDATION PROGRAM, HAS AWARDED NEARLY $51 MILLION WORLDWIDE IN RESEARCH GRANTS TOWARD THE STUDY OF GLAUCOMA. NGR-SUPPORTED RESEARCH HAS FOCUSED ON THE EYE-BRAIN CONNECTION, HOW PRESSURE BUILDUP IN THE EYE CAN AFFECT SYNAPTIC NERVE COMMUNICATIONS, NEUROPROTECTION AND OPTIC NERVE REGENERATION, DISCOVERING GLAUCOMA RISK GENES, AI/DEEP LEARNING AND ADAPTIVE OPTICS, SLEEP DISTURBANCE AND GLAUCOMA RISK, DEVELOPING EARLY GLAUCOMA SCREENING, AND PURSUING NOVEL GENETIC COUNSELING AND COMMUNICATION STRATEGIES, AMONGST OTHER INNOVATIVE PURSUITS. NGR GRANTS ARE AVAILABLE TO GLAUCOMA RESEARCHERS WORLDWIDE. NGR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM YOUNG SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON SCIENTIFIC MERIT. DURING THE FISCAL YEAR ENDING MARCH 31, 2024, NGR AWARDED $1,549,923 IN PEER-REVIEWED GRANT AWARDS FOR 9 NEW PROJECTS. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES F & I. IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, NATIONAL GLAUCOMA RESEARCH PROVIDES EXPERT-VETTED RESOURCES ON DETECTING, TREATING, AND LIVING WITH THE DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG. |
| FORM 990, PART VI, SECTION B, LINE 11B | A DRAFT OF THE FEDERAL FORM 990 IS DISTRIBUTED TO THE AUDIT COMMITTEE FOR REVIEW PRIOR TO BEING SUBMITTED TO THE INTERNAL REVENUE SERVICE. THE DRAFT FEDERAL FORM 990 IS DISTRIBUTED EARLY ENOUGH TO PROVIDE EACH COMMITTEE MEMBER WITH A REASONABLE AMOUNT OF TIME FOR REVIEW AND SUBMISSION OF QUESTIONS OR COMMENTS PRIOR TO THE FILING DEADLINE. THE FINAL FEDERAL FORM 990 IS DISTRIBUTED TO EACH MEMBER OF THE FULL BOARD OF DIRECTORS PRIOR TO BEING FILED WITH THE INTERNAL REVENUE SERVICE. THE DRAFT OR FINAL FEDERAL FORM 990 MAY BE DISTRIBUTED IN PERSON, BY REGULAR MAIL, E-MAIL, OR FAX. |
| FORM 990, PART VI, SECTION B, LINE 12C | BRIGHTFOCUS HAS ALL EMPLOYEES, OFFICERS, AND DIRECTORS AGREE TO THE CODE OF CONDUCT THAT INCLUDES ADHERENCE TO THE CONFLICT OF INTEREST AND IMPLEMENTATION POLICY. EACH BOARD DIRECTOR, OFFICER, AND EMPLOYEE IS REQUIRED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE STATEMENT ANNUALLY. EMPLOYEES MEET ANNUALLY WITH THE BRIGHTFOCUS' CHIEF COMPLIANCE OFFICER TO REVIEW THEIR CONFLICT OF INTEREST STATEMENTS, AND GIVE AN ANNUAL CONFLICT OF INTEREST COMPLIANCE REPORT TO THE BOARD CHAIR AND VICE CHAIR. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE PRESIDENT/CEO AND/OR BRIGHTFOCUS' LEGAL COUNSEL AND, IF APPROPRIATE AND NECESSARY, THEN TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION. THE DIRECTOR'S AND OFFICER'S STATEMENTS ARE REVIEWED BY THE BRIGHTFOCUS LEGAL COUNSEL. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION. AT THE TIME OF THE BRIGHTFOCUS DISCUSSION AND DECISION CONCERNING A CONFLICT OF INTEREST, THE CONFLICTED PARTY IS NOT PRESENT IN THE MEETING. |
| FORM 990, PART VI, SECTION B, LINE 15 | BRIGHTFOCUS' BOARD OF DIRECTORS HAS OVERALL AUTHORITY AND RESPONSIBILITY FOR APPROVING THE ANNUAL BUDGET WHICH INCLUDES SALARY AND BENEFITS FOR ALL EMPLOYEES AT EVERY LEVEL INCLUDING NON-DIRECTOR OFFICERS AND KEY EMPLOYEES. ALL PAY ADJUSTMENTS ARE MADE ON A YEARLY BASIS EFFECTIVE APRIL 1ST, THE BEGINNING OF THE BRIGHTFOCUS FISCAL YEAR. BEFORE APPROVING THE COMPENSATION OF THE PRESIDENT/CEO, THE BOARD DETERMINES THE TOTAL COMPENSATION TO BE PROVIDED BY BRIGHTFOCUS TO THE PRESIDENT/CEO IS REASONABLE CONSIDERING THE POSITION, RESPONSIBILITY AND QUALIFICATION OF THE POSITION HELD, INCLUDING THE RESULT OF AN EVALUATION OF PRIOR PERFORMANCE FOR BRIGHTFOCUS, IF APPLICABLE. THE PRESIDENT/CEO IS EVALUATED YEARLY BY THE BOARD OF DIRECTORS USING AN IN-DEPTH GOAL ATTAINMENT STRUCTURE, THAT INCLUDES A SELF-ASSESSMENT AND A BOARD OF DIRECTOR'S ASSESSMENT AND EVALUATION AGAINST SET GOALS, OUTCOMES, AND DELIVERABLES. IN ADDITION, THE BOARD OF DIRECTORS PERIODICALLY ENGAGES AN OUTSIDE CONSULTANT TO OBTAIN AND CONSIDER APPROPRIATE DATA, INCLUDING A SALARY SURVEY, WHICH INCLUDES INFORMATION COMPILED FROM THE FEDERAL FORM 990 OF OTHER ORGANIZATIONS, CONCERNING COMPENSATION PAID TO CEOS IN SIMILAR CIRCUMSTANCES. IN MAKING THE DETERMINATION, THE BOARD OF DIRECTORS CONSIDERS TOTAL COMPENSATION TO INCLUDE THE SALARY AND VALUE OF ALL BENEFITS PROVIDED BY BRIGHTFOCUS TO THE INDIVIDUAL IN PAYMENT FOR SERVICES. AT THE TIME OF THE BRIGHTFOCUS BOARD DISCUSSION AND DECISION CONCERNING THE PRESIDENT/CEO'S COMPENSATION, THE PRESIDENT/CEO IS NOT PRESENT IN THE MEETING. THE BOARD OF DIRECTORS SHALL SET FORTH THE BASIS FOR ITS DECISIONS WITH RESPECT TO COMPENSATION IN THE MINUTES OF THE MEETING AT WHICH THE DECISIONS ARE MADE, INCLUDING THE CONCLUSIONS OF THE EVALUATION AND THE BASIS FOR DETERMINING THAT THE INDIVIDUAL'S COMPENSATION WAS REASONABLE CONSIDERING THE EVALUATION AND COMPARABILITY DATA. THE PRESIDENT/CEO IS CHARGED WITH SETTING THE SALARIES OF ALL OTHER EMPLOYEES IN ACCORDANCE WITH A COMPENSATION STRUCTURE AND BUDGET APPROVED BY THE BOARD OF DIRECTORS. THE PRESIDENT/CEO AND HUMAN RESOURCES REVIEW EMPLOYEE COMPENSATION AND BENEFITS THAT INCLUDE KEY EMPLOYEES, BY PERIODICALLY ENGAGING AN OUTSIDE CONSULTANT TO CONDUCT COMPENSATION AND BENEFIT BENCHMARKING STUDIES THAT INCLUDE VARIOUS REGIONAL AND NATIONAL NON-PROFIT COMPENSATION REPORTS AND SURVEYS. COMPENSATION DELIBERATIONS AND DECISIONS INCLUDE THE REVIEW OF SELF AND SUPERVISORY EVALUATIONS OF EMPLOYEE PERFORMANCE COMPARED TO SET INDIVIDUAL AND ORGANIZATIONAL GOALS. |
| FORM 990, PART VI, SECTION C, LINE 19 | BRIGHTFOCUS MAKES ITS GOVERNING DOCUMENTS INCLUDING ITS ARTICLES OF INCORPORATION AND BYLAWS, THE FEDERAL FORM 1023, THE 501(C)(3) LETTER OF DETERMINATION FROM THE INTERNAL REVENUE SERVICE, CONFLICT OF INTEREST POLICY, AUDITED FINANCIAL STATEMENTS AND FEDERAL FORM 990 AVAILABLE TO THE PUBLIC UPON REQUEST. IN ADDITION, THE PUBLIC ALSO HAS ACCESS TO THE ANNUAL REPORT, AUDITED FINANCIAL STATEMENTS, THE 501(C)(3) LETTER OF DETERMINATION FROM THE INTERNAL REVENUE SERVICE, AND FEDERAL FORM 990 ON ITS WEBSITE AT WWW.BRIGHTFOCUS.ORG. |
| FORM 990, PART XI, LINE 9: | RECOVERIES OF PRIOR YEAR GRANTS 435,223. CHANGE IN PRESENT VALUE OF GRANTS -129,218. |
Schedule R IRS990ScheduleR
Id Disregarded Entities IdDisregardedEntitiesGrp (2 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Total IncomeTotalIncomeAmt | End Of Year AssetsEndOfYearAssetsAmt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt |
|---|---|---|---|---|---|---|---|---|---|
| NATIONAL DEVELOPMENT LLC | |||||||||
| 22512 GATEWAY CENTER DRIVE | CLARKSBURG | MD | 20871 | 237337229 | PROPERTY RENTAL AND MANAGEMENT | MD | $450,765 | $4,729,697 | BRIGHTFOCUS FOUNDATION |
| AMERICAN HEALTH ASSISTANCE LLC | |||||||||
| 22512 GATEWAY CENTER DRIVE | CLARKSBURG | MD | 20871 | 237337229 | OWNER OF BRIGHTFOCUS HEADQUARTERS | MD | $0 | $3,114,398 | BRIGHTFOCUS FOUNDATION |